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ABSTRACT OF THE DISSERTATION 
 
Mitochondrial Dynamics Controls T Cell Fate Through Metabolic Programming 
by 
Michael D. Buck 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2017 
Professor Erika L. Pearce, Chair 
Professor Eugene M. Oltz, Co-chair 
 
Activated effector T (TE) cells augment anabolic pathways of metabolism, such as aerobic 
glycolysis, while memory T (TM) cells engage catabolic pathways, like fatty acid oxidation 
(FAO). However, signals that drive these differences remain unclear. Mitochondria are metabolic 
organelles that actively transform their ultrastructure. Therefore, we questioned whether 
mitochondrial dynamics controls T cell metabolism. We show that TE cells have punctate 
mitochondria, while TM cells maintain fused networks. The fusion protein Opa1 is required for 
TM, but not TE cells after infection, and enforcing fusion in TE cells imposes TM cell 
characteristics and enhances antitumor function. Our data suggest that, by altering cristae 
morphology, fusion in TM cells configures electron transport chain (ETC) complex associations 
favoring oxidative phosphorylation (OXPHOS) and FAO, while fission in TE cells leads to 
cristae expansion, reducing ETC efficiency and promoting aerobic glycolysis. Thus 
mitochondrial remodeling is a signaling mechanism that instructs T cell metabolic programming. 
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Chapter 1: T Cell Metabolism Drives Immunity 
Published in the August 24th, 2015 issue of Journal of Experimental Medicine 
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Abstract 
 
Lymphocytes must adapt to a wide array of environmental stressors as part of their normal 
development, during which they undergo a dramatic metabolic remodeling process.  Research in 
this area has yielded surprising findings on the roles of diverse metabolic pathways and 
metabolites, which have been found to regulate lymphocyte signaling and influence 
differentiation, function and fate. In this review, we integrate the latest findings in the field to 
provide an up-to-date resource on lymphocyte metabolism. 
 
Introduction 
 
“Part of the secret of success in life is to eat what you like and let the food fight it out inside.” – 
Mark Twain 
 
Simply stated, we are what we eat. Our genetics coupled with environmental influences dictate 
how we metabolize the nutrients we consume and shape our growth, function, and overall health. 
The same principles hold true at the cellular level. Just as a track runner quickly engages their 
muscles to propel themselves from rest to sprint in response to a starting gun, pathogen-derived 
or inflammatory signals drive T cells out of quiescence, resulting in rapid modulation of gene 
expression and the acquisition of new functions. These changes range from increased production 
of cytokines and cytolytic molecules to the ability to undergo cell division and migration. 
Intimately integrated into this program of activation is the regulation of cellular metabolism. 
 
 3 
The engagement of specific metabolic pathways profoundly affects cell differentiation and 
function. Metabolic reprogramming is controlled by key receptor signaling events and growth 
factor cytokines, as well as availability of nutrients. In addition, metabolic products provide 
substrates that can alter the functional fate of a cell through post-translational modifications 
(PTMs) or epigenetic remodeling. Several recent articles have covered these and other emerging 
topics in T cell metabolism (Bird, 2015; Chapman and Chi, 2014; Lochner et al., 2015; 
O'Sullivan and Pearce, 2015; Palmer et al., 2015; Ramsay and Cantrell, 2015; Ron-Harel et al., 
2015). In this review, we provide a general but comprehensive overview of lymphocyte 
metabolism integrated with current research. Our focus will be on data and concepts derived 
primarily from T cell studies with tie-ins from other fields when relevant. 
 
  
 4 
T cell development and quiescence 
 
Although the bulk of T-cell metabolism research centers on mature T cells, even at their 
inception and throughout their development, T cells cycle through states of metabolic quiescence 
and activation. Hematopoietic stem cell progenitors that are double negative (DN) for CD4 and 
CD8 co-receptors migrate from the bone marrow and seed the thymus where they rearrange their 
antigen receptor gene loci to produce a functional T cell receptor (TCR). Signals from the 
receptor Notch1 maintain cell survival and are required to promote T-cell lineage commitment 
(Maillard et al., 2006; Pui et al., 1999; Radtke et al., 1999). Induced deletion of Notch1 during 
neonatal development results in arrest at the most immature DN1 (CD44+CD25-) stage (Radtke 
et al., 1999), while enforced expression of constitutively active Notch1 in bone marrow cells 
blocks B cell differentiation and instead causes the ectopic development of CD4+CD8+ double 
positive (DP) T cells (Pui et al., 1999). 
 
Successful expression of TCRβ with pTα and CD3 forms the pre-TCR and signals with Notch1 
to drive cells out of quiescence as they enter β-selection (Ciofani et al., 2004; Ciofani and 
Zuniga-Pflucker, 2005; Saint-Ruf et al., 1994). RAG recombinase expression declines and 
expression of the transferrin receptor CD71 and other nutrient transporters are induced as the 
cells proliferate (Ciofani and Zuniga-Pflucker, 2005; Kelly et al., 2007). Signaling from the pre-
TCR, Notch1, and the chemokine receptor CXCR4 converge to activate phosphatidylinositol 3-
kinase (PI3K); this stimulates the switch to anabolic metabolism (processes that supports the 
biosynthetic demands of proliferation) (Ciofani and Zuniga-Pflucker, 2005; Janas et al., 2010). 
Increased expression of the glucose transporter Glut1 is required during this stage and its 
 5 
expression is dependent on activation of the kinase Akt by PI3K (Juntilla et al., 2007; Swainson 
et al., 2005; Wieman et al., 2007). PI3K-Akt signaling also activates the mechanistic target of 
rapamycin (mTOR), and signals from this kinase augment the glycolytic metabolism used to 
support cell growth and proliferation (MacIver et al., 2013). 
 
Disruptions in PI3K signaling also affect the transition of DP thymocytes to single positive CD4 
and CD8 T cells and the development of natural killer T (NKT) cells, which require sustained 
signaling in order to join tcra Vα to distal Jα gene segments that define their invariant TCR 
(D'Cruz et al., 2010; Rodriguez-Borlado et al., 2003). PTEN (phosphatase and tensin homolog) 
is the principal negative regulator of the PI3K pathway. Thymocytes from mice that lack the 
microRNA cluster miR-181a1b1 have altered cellular metabolism due to a significant increase in 
PTEN expression (Henao-Mejia et al., 2013). Glucose uptake, measured by acquisition of the 
fluorescent glucose analog 2-NBDG, and glycolytic rate are reduced in these cells, and nutrient 
transporter expression is diminished. As a result of dysregulated PI3K signals, these mice have 
deficiencies in DP cells and completely lack NKT cells (Henao-Mejia et al., 2013). 
 
The cytokine interleukin (IL)-7 has a pivotal role in ensuring the survival of developing and 
quiescent naïve T cells by increasing expression of the anti-apoptotic factor Bcl-2 (B-cell 
lymphoma 2) (Akashi et al., 1997; Maraskovsky et al., 1997; Tan et al., 2001; Yu et al., 2003). 
Mice deficient in IL-7 or the IL-7Rα chain have defects in T cell development (Peschon et al., 
1994; von Freeden-Jeffry et al., 1995). IL-7 signals through the JAK3-STAT5 pathway, but can 
also activate PI3K (Pallard et al., 1999; Wofford et al., 2008). A recent study suggests that in 
addition to maintaining the survival of developing lymphocytes, IL-7 signaling promotes the 
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growth and proliferation of DN4 cells by increasing levels of trophic receptors, such as CD71 
and the amino acid transporter CD98 (Boudil et al., 2015; Pearson et al., 2012), activities that 
previously were attributed mainly to Notch1 signaling. However, Notch1 can induce IL-7Rα 
expression and therefore its effects could be downstream of IL-7 signals (Gonzalez-Garcia et al., 
2009; Magri et al., 2009). 
 
Mature naïve T cells exit from the thymus into the periphery. As quiescent cells they primarily 
oxidize glucose-derived pyruvate in their mitochondria via oxidative phosphorylation 
(OXPHOS), or use fatty acid oxidation (FAO) to generate ATP (Figure 1) (Fox et al., 2005; 
Pearce and Pearce, 2013; Pearce et al., 2013; van der Windt and Pearce, 2012; Wang et al., 
2011). A balance between tonic TCR signals and IL-7 are needed to sustain naïve T cells. 
Homeostatic proliferation of naïve T cells is supported by TCR ligation with self-peptides 
presented on major histocompatibility complex (MHC) molecules in the periphery (Ernst et al., 
1999; Goldrath and Bevan, 1999; Muranski et al., 2000). However, unrestrained Akt activation, 
or deletion of negative regulators of TCR stimulation, leads to loss of quiescence (Yang et al., 
2011). T cells defective in tuberous sclerosis complex 1 (TSC1), a negative regulator of mTOR 
signaling, prematurely exit from quiescence and have increased rates of apoptosis and 
hyperactive responses to TCR stimulation (Yang et al., 2011). In addition, TCR mediated PI3K-
Akt activation downregulates IL-7Rα (Cekic et al., 2013), but as discussed above, IL-7 signaling 
is critically essential to prevent apoptosis and ensure survival of the naïve T cell pool (Rathmell 
et al., 2001; Surh and Sprent, 2008). A recent study showed that the metabolite adenosine, which 
is a byproduct of metabolic activity, suppresses TCR signaling in a dose dependent manner 
(Cekic et al., 2013). The G-protein-coupled adenosine receptor subtype A2AR is predominantly 
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expressed in T cells. Binding with adenosine activates cAMP-dependent protein kinase A (PKA), 
which suppresses TCR mediated activation of the PI3K pathway and prevents IL-7Rα 
downregulation (Cekic et al., 2013).  
 
Activation and effector T cell differentiation 
 
Metabolic reprogramming during T cell activation 
Once in the periphery, a mature naïve T cell is like a bomb, lying dormant in the lymphoid 
organs and circulation until it is triggered to activate and ‘explode’ in a proliferative chain 
reaction. T-cell activation stimulated by TCR ligation and binding with costimulatory molecules 
induces metabolic remodeling of the naïve T cell to a program of anabolic growth and biomass 
accumulation; this is marked by the engagement of aerobic glycolysis, a process in which 
glucose is converted into lactate even though sufficient oxygen is present to support glucose 
catabolism via the tricarboxylic acid (TCA) cycle and OXPHOS (Figure 1) (MacIver et al., 
2013; Vander Heiden et al., 2009). Although aerobic glycolysis is less efficient than OXPHOS at 
yielding an abundance of ATP per molecule of glucose, aerobic glycolysis can generate 
metabolic intermediates important for cell growth and proliferation, and provides a way to 
maintain redox balance (NAD+/NADH) in the cell (Figure 2) (Anastasiou et al., 2011; 
Macintyre and Rathmell, 2013; Vander Heiden et al., 2009). For example, glucose-6-phosphate 
and 3-phosphoglycerate (3PG) produced during glycolysis can be metabolized in the pentose 
phosphate and serine biosynthesis pathways, respectively, donating important precursors for 
nucleotide and amino acid synthesis (Pearce et al., 2013; Wang et al., 2011). Glucose can also 
enter the mitochondria as pyruvate, where it is converted to acetyl-CoA and joins the TCA cycle 
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by condensing with oxaloacetate to form citrate. Breakdown of substrates in the TCA cycle not 
only provides reducing equivalents for OXPHOS, but also precursors for biosynthesis. Glucose-
derived citrate can be exported into the cytosol to generate acetyl-CoA by ATP citrate lyase 
(ACL) for use in lipid synthesis (Bauer et al., 2005; DeBerardinis et al., 2008; Hatzivassiliou et 
al., 2005). Similarly, oxaloacetate can be used to produce aspartate, an additional precursor for 
generating nucleotides (Figure 2) (DeBerardinis et al., 2007). 
  
Several transcription factors and signaling pathways coordinately support and regulate this 
change in T-cell metabolic programs following activation. Growth factor cytokines such as IL-2 
and ligation of costimulatory molecules promote the switch to glycolysis through the 
enhancement of nutrient transporter expression and activation of the key metabolic regulator 
mTOR (Figure 1) (Frauwirth et al., 2002; Jones and Thompson, 2007; Kolev et al., 2015; 
Wieman et al., 2007). Existing as two complexes, mTORC1 and mTORC2, this kinase integrates 
extrinsic and intrinsic signals related to nutrient levels, energy status, and stress to induce 
changes in cellular metabolism, growth, and proliferation (Laplante and Sabatini, 2012). CD28 
ligation enhances PI3K activity, which recruits 3-phosphoinositide-dependent protein kinase-1 
(PDPK1) and Akt. PDPK1, together with mTORC2, phosphorylates Akt, which in turn activates 
mTORC1. Both Akt and mTOR promote aerobic glycolysis and support effector T-cell 
differentiation, growth, and function (Delgoffe et al., 2011; Pollizzi et al., 2015). Akt regulates 
nutrient transporter expression and can phosphorylate the glycolytic enzyme hexokinase II, 
promoting its localization to the mitochondria and augmenting its enzymatic activity (John et al., 
2011; Miyamoto et al., 2008). mTORC1 activation increases protein translation via 
phosphorylation of 4E-BP1 and p70S6 kinase (Laplante and Sabatini, 2012) and promotes lipid 
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synthesis by activating SREBP2 (sterol regulatory element-binding protein 2) (Porstmann et al., 
2008).  
 
The upregulation of transcription factors c-Myc, estrogen-related receptor α (ERRα), and 
hypoxia inducible factor-1α (HIF-1α) coordinately drive the expression of genes involved in 
intermediary metabolism that fuel the rapid proliferation of effector T cells during clonal 
expansion (Doedens et al., 2013; Michalek et al., 2011; Wang et al., 2011). First discovered as an 
oncogene important for cell growth and proliferation (Cole, 1986; Sheiness et al., 1978), c-Myc 
has been shown to be a critical regulator of metabolic reprogramming following T-cell activation 
(Wang et al., 2011). c-Myc drives the expression of enzymes that promote aerobic glycolysis and 
glutaminolysis and coordinates these metabolic pathways with lipid, amino acid, and nucleic acid 
synthesis. However, c-Myc expression is not continually sustained after T-cell activation (Best et 
al., 2013; Nie et al., 2012). A recent study suggests that c-Myc induces the transcription factor 
AP4, which maintains the glycolytic transcriptional program initiated by c-Myc to support T-cell 
population expansion (Chou et al., 2014; Karmaus and Chi, 2014). HIF-1α, a transcription factor 
that responds to oxygen levels, also increases glucose uptake and catabolism through glycolysis 
(Finlay et al., 2012; Kim et al., 2006). Deletion of its negative regulator, von Hippel-Lindau 
(VHL), enhances HIF-1α mediated CD8 T-cell glycolysis and effector responses to persistent 
viral infection (Doedens et al., 2013).  
 
ROS signaling 
Although much of the attention on metabolic reprogramming in activated T cells has focused on 
the engagement of aerobic glycolysis, recent research has revealed the importance of 
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mitochondrial-driven activities in this process. In addition to energy production, the electron 
transport chain (ETC) is a major source of reactive oxygen species (ROS) (Turrens, 2003), which 
are important for T-cell responses (Figure 2) (Chaudhri et al., 1988; Devadas et al., 2002; Jones 
et al., 2007). T cells deficient for Rieske iron sulfur protein (RISP), a subunit of mitochondrial 
complex III, have impaired activation and antigen-specific T-cell expansion in vitro and in vivo 
due to defects in mitochondrial-derived ROS signaling (Sena et al., 2013). More recently, using a 
forward genetic screen, another group identified mice with enhanced CD8 T-cell responses to 
viral and tumor challenge (Okoye et al., 2015). The source of the heightened immunity gained 
after germline mutagenesis was found to be due to the increased expression of an orphan protein, 
identified as Lymphocyte Expansion Molecule (LEM). Interestingly, augmented OXPHOS and 
mitochondrial ROS levels were detected in CD8 T cells isolated after infection from these mice, 
whereas heterozygous LEM-deficient CD8 T cells had reduced OXPHOS and mitochondrial 
ROS levels. LEM helps stabilize a protein involved in inserting ETC complex proteins in the 
mitochondrial membrane, which may account for the increased ROS and enhanced proliferation 
evident in CD8 T cells from these mice (Okoye et al., 2015). 
 
While ROS is produced as a general by-product of mitochondrial metabolism, new studies have 
specifically linked the metabolite succinate to both the generation of ROS and activation of HIF-
1α in settings of inflammation or injury (Chouchani et al., 2014; Tannahill et al., 2013). Innate 
immune receptor activation increases intracellular succinate from glutamine via glutamine-
dependent anerplerosis and the γ-aminobutyric acid shunt pathway and this leads to HIF-1α 
stabilization and activation (Tannahill et al., 2013). During ischaemia reperfusion injury, which 
happens when blood supply to a tissue is disrupted and then restored, succinate accumulates 
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from reverse activity of the enzyme succinate dehydrogenase (SDH) and is rapidly oxidized 
upon reperfusion. This leads to over-reduction of the electron carrier coenzyme Q, causing 
reverse electron transport through mitochondrial complex I and subsequently, excessive ROS 
production (Chouchani et al., 2014; O'Neill, 2014). Given that mitochondrial ROS and HIF-1α 
activity are important for the metabolic reprogramming of naïve T cells after activation, it is 
interesting to speculate that the metabolite succinate may also support the transition from a naïve 
to an activated effector T cell. 
 
Metabolic programming of T helper cell differentiation 
Activation of T cells is intimately tied to the engagement of specific metabolic pathways, so it is 
no surprise that distinct metabolic programs also support the differentiation of CD4 T helper (Th) 
cells into their separate lineages. Initial studies found that suppression of mTOR with rapamycin 
promoted the generation of FoxP3+ T regulatory (Treg) cells even in the presence of Th17 
polarizing cytokines in vitro (Kopf et al., 2007), and genetic deletion of mTOR in T cells 
augmented production of Treg cells upon activation, but not Th1, Th2, or Th17 cells (Delgoffe et 
al., 2009). These results are consistent with the metabolic profiles of these cells: Th1, Th2, and 
Th17 cells strongly engage glycolysis via mTOR signaling, while Treg cells depend more on the 
oxidation of lipids (Figure 1) (Michalek et al., 2011). Th17 cells in particular have been found to 
heavily rely on glycolysis for their development and maintenance, stimulated by HIF-1α activity 
downstream of mTOR. Mice deficient in HIF-1α have increased generation of Treg cells, and 
blocking glycolysis with 2-Deoxy-D-glucose (2-DG) inhibits Th17-cell differentiation (Dang et 
al., 2011; Shi et al., 2011). Treg-cell homeostasis and survival depends on the delicate balance 
between mTORC1 activation from PI3K-Akt and regulation from PTEN (Huynh et al., 2015; 
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Shrestha et al., 2015; Zeng et al., 2013). Signaling through mTORC1 versus mTORC2 also 
selectively differentiates CD4 T cells into the Th1 and Th2 lineages, respectively, (Delgoffe et 
al., 2011; Lee et al., 2010), although activation of mTORC1 and its component Raptor is still 
required for T-cell exit from quiescence to begin the transition into Th2 cells (Yang et al., 2013). 
Less is known about T follicular helper (Tfh) cell metabolism compared to other T cell subsets, 
but their lineage-defining transcription factor Bcl6, has been shown to suppress glycolysis 
potentiated by c-Myc and HIF-1α (Johnston et al., 2009; Nurieva et al., 2009; Oestreich et al., 
2014).  
 
Substrate utilization in activated T cells 
 
Glucose is a key metabolic substrate for T cells. Upon T-cell activation, Glut1 traffics to the cell 
surface from intracellular vesicles (Frauwirth et al., 2002; Rathmell et al., 2000; Wieman et al., 
2007). Overexpression of Glut1 in mice results in larger naïve T cells and an increased number 
of CD44hi T cells, suggesting that glucose acquisition mediates early steps in T-cell activation, 
such as promoting activation marker expression and increasing cell size (Jacobs et al., 2008). 
Consistent with these observations, T cell-specific deletion of Glut1 impairs CD4 T-cell 
activation, clonal expansion, and survival (Macintyre et al., 2014). When deprived of glucose, 
CD8 T cells display defects in functional capacity with reduced IFN-γ, granzyme, and perforin 
production (Cham et al., 2008; Cham and Gajewski, 2005; Jacobs et al., 2008). More recently, it 
was shown that T cells can become activated and proliferate when glucose catabolism through 
aerobic glycolysis is limited as they can rely on OXPHOS (Chang et al., 2013; Sena et al., 2013). 
However, in this case, effector function is compromised such that cytokine production is 
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impaired due to posttranscriptional regulation by the glycolytic enzyme GAPDH. When 
disengaged from glycolysis, GAPDH can function as a RNA-binding protein (RBP) and prevent 
the translation of cytokine messenger RNAs containing AU rich elements in their 3’-UTRs 
(Chang et al., 2013). Therefore, in addition to providing precursors for biomass, augmenting 
aerobic glycolysis in activated T cells allows for the acquisition of full effector function. 
 
Amino acids 
While glucose is a critical substrate for T cells, glutamine is also essential during T-cell 
activation (Carr et al., 2010; Frauwirth et al., 2002; Wang et al., 2011). T cells increase the 
expression of glutamine transporters and their deletion impairs the transition to an effector T cell 
(Carr et al., 2010; Sinclair et al., 2013). Clear differences in concentrations of other amino acids 
also exist in quiescent compared to activated T cells, corresponding to their distinct metabolic 
requirements (Ananieva et al., 2014; Pearson et al., 2012). New research has begun to uncover 
the vast array of additional amino acid transporters and catabolizing enzymes that regulate amino 
acid levels, revealing previously unappreciated roles for amino acids in T-cell metabolism and 
function.  
 
Deficiency in the neutral amino acid transporter Slc7a5 (LAT1), which transports leucine, was 
found to prevent the ability of both CD4 and CD8 T cells to metabolically reprogram and 
undergo clonal expansion or effector differentiation (Hayashi et al., 2013; Sinclair et al., 2013). 
These cells had impaired mTORC1 activation and the inability to induce key metabolic 
processes, such as glutamine and glucose uptake (Sinclair et al., 2013). This deficiency, 
however, did not impair the ability of CD4 T cells to differentiate into Treg cells. Leucine can 
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activate mTOR via leucyl-tRNA synthetase, and thus it is not surprising that reduced leucine 
uptake impairs mTOR activation (Han et al., 2012). However the effects of Slc7a5 deficiency 
was more severe than those induced by mTOR inhibition using rapamycin (Sinclair et al., 2013), 
suggesting either that rapamycin may not have completely blocked mTOR activation, or that 
leucine deficiency has effects over and above limiting mTOR activation (Powell, 2013; Thoreen 
et al., 2009). Additionally, it was observed that although no overt decrease in global protein 
expression occurred in Slc7a5-deficient cells, protein expression of the key metabolic 
transcription factor c-Myc was diminished, despite its increased mRNA expression upon 
activation (Sinclair et al., 2013). This raises the intriguing question of whether leucine deficiency 
results in posttranslational regulation of c-Myc expression. Alternatively this effect could simply 
be due to a limitation in the supply of amino acids in Slc7a5-deficient cells, which is not 
sufficient to keep up with the demands of synthesizing proteins such as c-Myc, which have a 
short half-life (Sinclair et al., 2013). 
 
Results from another study suggest that modulation of intracellular leucine concentrations can be 
used to regulate metabolic reprogramming. It was found that the expression of the cytosolic 
branched chain aminotransferase (BCATc), which can reduce intracellular leucine concentrations 
through a transamination reaction, limited mTORC1 activation (Ananieva et al., 2014). BCATc 
expression was upregulated upon CD4 T-cell activation, and T cells that lacked BCATc had 
increased intracellular leucine, which correlated with enhanced activation of mTORC1 and 
glycolytic phenotype. Increased BCATc expression has been observed in anergic T cells, which 
have impaired metabolic function (Ananieva et al., 2014; Zheng et al., 2009). These data could 
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suggest that leucine depletion by BCATc contributes to T-cell anergy through suppression of 
mTOR activity.  
 
The alanine serine and cysteine transporter system (ASCT2/Slc1a5), which also transports 
glutamine, is another solute carrier whose expression increases following T-cell activation 
(Levring et al., 2012). It was recently found that loss of ASCT2 decreased glutamine import and 
impaired OXPHOS and glucose metabolism in activated CD4 T cells (Nakaya et al., 2014). 
Surprisingly, the loss of ASCT2 did not inhibit proliferation or IL-2 production. However, 
ASCT2-deficient cells cultured in vitro had a decreased ability to differentiate into Th1 and Th17 
cells, but not Th2 or Treg cells. Interestingly, glutamine transport into cells can substantially 
enhance leucine transport via Slc7a5, as increased intracellular glutamine levels result in 
glutamine export and concomitant import of leucine by this transporter (Nicklin et al., 2009). 
Supporting this additional role for glutamine in T-cell activation, addition of leucine to T cells 
lacking ASCT2 helps rescue their polarization defects (Nakaya et al., 2014). 
 
Depletion of extracellular arginine has been found to impair T-cell proliferation and aerobic 
glycolysis, but not mitochondrial OXPHOS (Fletcher et al., 2015). However, provided that 
extracellular concentrations of citrulline are sufficient, T cells can partially compensate by 
synthesizing arginine de novo in an argininosuccinate 1 (ASS1)-dependent process (Fletcher et 
al., 2015; Qualls et al., 2012; Tarasenko et al., 2015). One study suggested that ASS1 activity 
may contribute to T-cell function in ways beyond simple synthesis of arginine, as deletion of 
ASS1 can negatively impact in vitro Th1 and Th17 cell polarization, even in the presence of 
extracellular arginine (Tarasenko et al., 2015). Arginine metabolism also has a role in 
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macrophage polarization and dictating metabolic phenotype (Galvan-Pena and O'Neill, 2014; 
Rath et al., 2014), but whether arginine metabolism also has such roles in T cells remains to be 
determined.   
 
A recent study suggests that intracellular recycling of amino acids also contributes to T-cell 
amino acid homeostasis. Deficiency in cytosolic protease tripeptidyl peptidase II (TPPII), which 
digests proteins for the recycling of amino acids, lead to increased sensitivity to perturbations in 
intracellular amino acids concentrations, impaired IFN-γ production, and a susceptibility to viral 
infections (Lu et al., 2014). Lack of TPPII activity in both human and murine T cells resulted in 
impaired glycolysis due to enhanced degradation of the key glycolytic enzyme hexokinase II, an 
effect that likely contributed to their impaired cytokine production (Lu et al., 2014). Another 
study also found that TPPII deficiency caused susceptibility to viral infections, although under 
these particular experimental conditions, defects in cytokine production were not observed and 
the T-cell dysfunction was attributed to premature immunosenescence (Stepensky et al., 2015). 
Although it remains to be tested, it may be possible that this premature cell senescence could be 
linked to reduced glycolytic flux. In a model of oncogenic stress-induced senescence, inhibition 
of hexokinase II or glucose uptake induces senescence in human epithelial cells (Gitenay et al., 
2014).   
 
Many products of amino acid catabolism also have important non-anaplerotic roles that can alter 
cell signaling and function. The metabolic byproduct of tryptophan catabolism, kynurenine, can 
ligate the aryl hydrocarbon receptor and enhance polarization of CD4 T cells to a Treg 
phenotype (Mezrich et al., 2010; Opitz et al., 2011).  Another example of this is catabolism of 
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phenylalanine by interleukin-4-induced gene 1 protein (IL4I1). When highly expressed by 
tumors or APCs, IL4I1 can inhibit T cell proliferation (Boulland et al., 2007; Lasoudris et al., 
2011). This effect appears to be due to the production of H2O2, a product of phenylalanine 
catabolism. IL4I1 is also expressed in Th17 and Treg cells (Santarlasci et al., 2012; Scarlata et 
al., 2015). The specific purpose for IL4l1 expression in these T-cell subsets remains ambiguous, 
although its expression in Th17 cells was speculated to have a self-regulatory role, where its 
induction led to diminished proliferation (Santarlasci et al., 2012). However given that low 
concentrations of H2O2 can act as a signaling molecule (Veal et al., 2007), IL4I1 might also play 
a role in cell signaling pathways independent of mechanisms that inhibit proliferation.    
 
Fluctuations in environmental amino acid concentrations, as well as metabolic products from 
amino acid catabolism, can dramatically alter T-cell activity and polarization. A well 
documented example of this is indoleamine-2,3-dioxygenase (IDO)-mediated tryptophan 
catabolism. IDO, which is often expressed at high levels by antigen presenting cells (APCs) or 
tumor cells, can deplete tryptophan within a tissue microenvironment, and this in turn can lead to 
inhibition of effector T-cell proliferation and induction of anergy (Munn et al., 2002; Uyttenhove 
et al., 2003). Depletion of tryptophan causes activation of the integrated stress response inducer 
general control nonderepressible 2 (GCN2) kinase, which results in the inhibition of translation 
initiation and metabolic remodeling (Castilho et al., 2014; Guo and Cavener, 2007; Munn et al., 
2005).  
 
Studies into the interactions of APCs with T cells have highlighted multiple pathways through 
which APCs modulate extracellular concentrations of amino acids, or their catabolic products, to 
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regulate T-cell responses. In a tumor, TGF-β-producing dendritic cells (DCs) can enhance 
expression of transporters for histidine, leucine, valine, and tryptophan, depleting these amino 
acids from the extracellular microenvironment and directly impairing T-cell proliferation 
(Angelini et al., 2002). Treg cells can also enhance expression of particular amino acid 
catabolizing enzymes, including arginase 1, histidine decarboxylase, threonine dehydrogenase, 
and IL4I1, in skin grafts and bone marrow derived DCs (Cobbold et al., 2009). Limitations in 
these amino acids, singularly or in combination, enhanced Treg-cell polarization when T cells 
were activated in vitro (Cobbold et al., 2009). Although depletion of amino acids from the 
microenvironment appears to be a way in which APCs can negatively regulate T-cell activity, the 
converse also occurs, whereby APCs can support T-cell activation through supplementing a 
microenvironment. For example, DCs and monocytes can release cysteine, which is thought to 
support T-cell activation and function (Angelini et al., 2002; Sido et al., 2000). Cysteine supply 
is a limiting factor in T-cell proliferation and is used extensively for protein and glutathione 
synthesis, as well as providing beneficial catabolic products, such as taurine, which may support 
T-cell function through regulating osmolality (Kaesler et al., 2012; Sikalidis, 2015).   
 
Lipid metabolism 
Lipids or fatty acids encompass another critical substrate group for T cells. They are a vital 
component of cell membranes, provide a high yielding energy source, and can also supply 
substrates for cell signaling and PTMs (Lochner et al., 2015; Thurnher and Gruenbacher, 2015). 
Following T-cell activation, the demand for lipids rapidly increases. Within 24 hours, in vitro 
activated T cells augment fatty acid synthesis (FAS) while concomitantly decreasing FAO, thus 
enhancing the accumulation of fatty acid metabolites needed for membrane synthesis (Wang et 
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al., 2011). c-Myc and mTOR have important roles in coordinating these metabolic changes 
(Wang et al., 2011; Yang et al., 2013), and SREBP transcription factors are critical for 
reprogramming lipid metabolism (Kidani et al., 2013). SREBPs induce expression of genes 
involved in FAS and mevalonate pathways, which supply de novo synthesized fatty acids and 
cholesterol, respectively (Thurnher and Gruenbacher, 2015). CD4 T cells deficient in Raptor, and 
thus mTORC1 signaling, have impaired de novo FAS, most likely due to reduced expression of 
SREBP1 and SREBP2 protein (Yang et al., 2013).  
 
Loss of SREBP function in CD8 T cells results in a failure to induce metabolic pathways needed 
for clonal expansion during a viral infection (Kidani et al., 2013). Exogenous cholesterol rescues 
the defects in SREBP-deficient T cells, suggesting that at least within this context, a lack of 
cholesterol is the main limiting factor. This requirement for cholesterol synthesis is consistent 
with results which show that perturbing sterol homeostasis in activated T cells – by activating the 
liver X receptor (LXR), which targets genes that are involved in cholesterol cellular export – 
impairs T-cell proliferation. The inhibitory effect of LXR activation can be overcome through 
the addition of mevalonate, a cholesterol precursor (Bensinger et al., 2008). Inhibition of 3-
hydroxy-3-methylgutaryl-coenzymeA (HMG-CoA) reductase, an enzyme in the mevalonate 
pathway, results in a Th2-cell bias in the experimental autoimmune encephalomyelitis (EAE) 
disease model, due to impaired biosynthesis of isoprenoids and a subsequent reduction in 
prenylation of Ras and RhoA GTPases (Youssef et al., 2002). These data suggest that in addition 
to cholesterol homeostasis, other products of the mevalonate pathway can also influence T-cell 
differentiation. The impact of commonly used drugs that lower cholesterol by inhibiting HMG-
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CoA reductase can affect both prenylation and cholesterol synthesis, and thus it is plausible these 
drugs have multiple effects on activated T cells. 
 
The synthesis of fatty acids is also important for effector T-cell function. Although activated T 
cells readily acquire and use extracellular fatty acids, it appears that there may also be cell-
intrinsic requirements for de novo synthesized fatty acids (Berod et al., 2014; Lee et al., 2014; 
O'Sullivan and Pearce, 2014; O'Sullivan et al., 2014). Inhibition of acetyl-CoA carboxylase 1 
(ACC1), an enzyme in FAS, was shown to limit Th17-cell differentiation and promote the 
development of Treg cells. This effect translated into improved disease outcomes in EAE (Berod 
et al., 2014). Inhibition of ACC1 impaired phospholipid synthesis in Th17 cells while also 
impairing glycolytic flux, both through aerobic glycolysis and the TCA cycle. In contrast, Treg 
cells were able to sustain their requirements for fatty acids through acquisition from extracellular 
sources (Berod et al., 2014). ACC1 deficiency also impairs Th1 and Th2 development, 
suggesting that CD4 effector T cells have a common requirement for FAS (Berod et al., 2014).  
In contrast, T cell-specific deletion of ACC1 does not impair CD8 effector T-cell development 
after infection, although effector T-cell expansion is diminished due to increased cell death, 
indicating that FAS is required for the persistence of CD8 effector T cells (Lee et al., 2014). 
Collectively, these findings suggest that there are varying requirements for de novo synthesized 
fatty acids between different T-cell subsets. Interestingly, defects following ACC1 inhibition in 
either Th17 cells or CD8 effector T cells can be rescued through the addition of excess free fatty 
acids to the media (Berod et al., 2014; Lee et al., 2014), indicating that these cells can 
compensate for the lack of FAS if the extracellular fatty acid supply is plentiful. It has also been 
observed that addition of extracellular fatty acids can enhance T-cell proliferation (Gorjao et al., 
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2007). It is plausible that the demand for fatty acids is so substantial in these highly proliferative 
populations that de novo FAS can be supplemented through extracellular uptake. This concept 
would be consistent with a recent study suggesting that lipid released from adipose tissue may 
enhance T-cell proliferation in vivo (Kim et al., 2015b). Responses to TNF-mediated signaling in 
the hypothalamus induced B- and T-cell proliferation in the spleen, an effect mediated by an 
induction of lipolysis through sympathetic nervous system signaling to adipose tissue and a 
resultant increase in circulating leptin and free fatty acids (Kim et al., 2015a).   
 
Although in general the balance of FAS to FAO within effector T-cell populations is weighted 
heavily towards FAS, effector T cells can utilize FAO (Byersdorfer et al., 2013; O'Sullivan et al., 
2014). Given that the demand for energy is high in these cells, it is likely that they need some 
metabolic flexibility in their fuel sources, an idea that is consistent with recent work highlighting 
the importance of adenosine monophosphate-activated protein kinase (AMPK) in effector T-cell 
function (Blagih et al., 2015). The extent to which FAO occurs in effector T cells is likely to be 
highly context dependent, in part due to the heterogeneity of this population of cells during an 
immune response. Studies using animal models of graft versus host disease (GvHD) have found 
that alloreactive T cells increase fatty acid uptake and enhance FAO compared to other effector 
T cells (Byersdorfer et al., 2013; Gatza et al., 2011; Glick et al., 2014). Suppressing Akt during 
activation can induce a metabolic profile suggestive of FAO utilization (Crompton et al., 2015), 
and culturing CD8 effector T cells in low glucose enhances FAO (O'Sullivan et al., 2014). A 
recent report also found that inhibition of T cell signaling through ligation of PD-1 induces 
changes in the metabolic profile of activated T cells, including decreased aerobic glycolysis and 
enhanced FAO (Patsoukis et al., 2015). Collectively, these data suggest that the utilization of 
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FAO in effector T cells may be influenced by a number of factors such as activation state, 
exposure to antigen, inflammatory signals, and micro-environmental nutrient availability.  
 
Memory T cell metabolism 
 
Effector T cell populations contract following pathogen clearance and undergo apoptosis, leaving 
behind a small population of long-lived memory T cells that can respond vigorously upon 
antigen rechallenge (Williams and Bevan, 2007). Although both naïve and memory T cells 
acquire effector functions upon activation, memory T cells have an accelerated response to 
antigen, proliferate faster, and produce more cytokines than their naïve counterparts. Work from 
our laboratory, and others, have shown that changes in metabolism also drive memory T-cell 
development (Figure 1) (Araki et al., 2009; Pearce et al., 2009; Rao et al., 2010). 
 
AMPK and mTOR 
Increases in intracellular AMP to ATP concentrations activate the energy stress sensor AMPK, a 
signal that also promotes FAO (Jones and Thompson, 2007). AMPK is important for the 
development of memory T cells and administration of the metabolic stressor and AMPK 
activator metformin enhances the generation of memory T cells following infection (Pearce et 
al., 2009; Rolf et al., 2013). In addition, AMPK allows for effector T cells to metabolically adapt 
during nutrient stress and modulates T-cell effector function through suppression of mTOR 
(Blagih et al., 2015; MacIver et al., 2011; Tamas et al., 2006). Inhibiting mTOR with rapamycin 
boosts memory T-cell development in vivo (Araki et al., 2009; Pearce et al., 2009; Rao et al., 
2010). Loss of the mTORC1 negative regulator TSC1 compromises formation of memory T-cell 
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precursors that are present during the primary effector response (Kaech et al., 2003; Shrestha et 
al., 2014). Similarly, suppressing mTORC2 fosters memory T-cell generation (Pollizzi et al., 
2015). Inhibition of mTOR and activation of AMPK also strongly stimulate the catabolic process 
of autophagy. Autophagy has been shown to support T-cell viability and bioenergetics after 
activation (Hubbard et al., 2010; Pua et al., 2007). Consistent with the idea that activation of 
catabolic pathways promotes the development of memory T cells, a recent study found that 
deletion of the autophagy molecules Atg5 or Atg7 compromised the formation of CD8 memory 
T cells after viral infection (Xu et al., 2014). 
 
FAO and mitochondria 
Work from our lab has shown that CD8 memory T cells are dependent on FAO for their 
development, long-term persistence, and ability to respond to antigen stimulation (Figure 1) 
(Pearce et al., 2009; van der Windt et al., 2012; van der Windt et al., 2013). Enhancing FAO in 
memory T cells through increased expression of carnitine palmitoyltransferase 1a (CPT1a) – a 
critical mitochondrial transporter of long chain fatty acids and rate limiting step to β-oxidation – 
increases CD8 memory T-cell numbers after infection (van der Windt et al., 2012). During an 
immune response, common γ chain cytokines like IL-15 and IL-7 have an essential role in 
supporting catabolic metabolism by promoting mitochondrial biogenesis, CPT1a expression, and 
FAO (van der Windt et al., 2012). As a result, memory T cells have increased mitochondrial 
mass and greater spare respiratory capacity (SRC) compared to naïve and effector T cells, which 
endows them with a bioenergetic advantage for survival and recall after antigen rechallenge 
(Gubser et al., 2013; van der Windt et al., 2012; van der Windt et al., 2013). Interestingly, a 
study investigating heterologous prime-boost vaccination found that memory T-cell 
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differentiation is hastened and enhanced after secondary or tertiary immunization, including 
acquisition of substantially greater mitochondrial mass and SRC (Fraser et al., 2013). In a sense, 
memory T cells are metabolically primed and ready to respond to secondary infections. This idea 
has recently been extended to innate immune cells under the novel concept of “trained 
immunity” whereby metabolic priming confers superior immunity to a secondary pathogenic 
insult (Cheng et al., 2014). Previous engagement of aerobic glycolysis in monocytes driven by 
mTOR and HIF-1α was found to induce epigenetic modifications that endowed them with 
enhanced function against other infections (Cheng et al., 2014). 
 
The specific role of FAO in promoting memory T-cell development and survival remains to be 
elucidated, but it appears that metabolic reprogramming associated with FAO enhances 
mitochondria-associated processes. Induction of FAO in memory T cells enhances SRC, which is 
the reserve capacity of mitochondria to produce energy over and above normal energy outputs 
(van der Windt et al., 2012). This parameter is probably important for the longevity of memory 
cells, especially in times of stress or nutrient restriction, conditions that may present themselves 
when infection is resolved and growth factor signals are scarce. Surprisingly, endothelial cells, 
unlike most other cell types, use carbon derived from FAO for nucleotide synthesis and 
proliferation (Schoors et al., 2015), providing another way in which FAO supports cell function. 
 
Another unexpected discovery was that memory T cells preferentially use de novo FAS to fuel 
FAO (O'Sullivan et al., 2014). Specifically, CD8 memory T cells utilize glucose to produce 
triacylglycerides (TAGs) that are subsequently hydrolyzed by lysosomal acid lipase (LAL) to 
support mitochondrial FAO (O'Sullivan and Pearce, 2014). It was also recently shown that 
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glucose metabolism is critical for CD4 memory T-cell survival, and this is controlled by Notch 
signaling (Maekawa et al., 2015). The requirement for FAS in CD8 memory T cells is supported 
by a recent study showing that glycerol import into the cell via IL-7-induced aquaporin-mediated 
transport is required for memory T-cell longevity (Cui et al., 2015). Glycerol is the molecular 
backbone for TAGs. Aquaporin 9 (AQP9)-deficient T cells had reduced glycerol import and 
TAG synthesis and impaired memory T-cell survival following viral infection (Cui et al., 2015).  
 
The reasons why CD8 memory T cells synthesize and then catabolize fatty acids in an apparently 
futile cycle rather than simply acquire extracellular fatty acids are not understood. However, this 
synthesis/catabolism cycle has also been shown to occur in muscle and adipose tissues (Dulloo et 
al., 2004; Yu et al., 2002). If viewed on a purely energetic level, this process appears counter-
productive, as there would be no net gain in ATP. It is possible that building and burning fatty 
acids allows memory T cells to sustain their glycolytic and lipogenic machinery while 
maintaining mitochondrial health during times of quiescence, allowing for the rapid recall ability 
that is characteristic of memory T cells following antigen recognition and activation (Gubser et 
al., 2013; van der Windt et al., 2013). It could also potentially provide a mechanism for 
balancing redox state or metabolic intermediates. An energetically futile cycle has been 
described in yeast grown in glucose rich media, whereby trehalose cycling provides a buffer 
system to maintain intracellular phosphate levels and balance glycolytic intermediates (van 
Heerden et al., 2014). 
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Emerging topics and concluding remarks 
 
It is an exciting time for the field of immunometabolism. While the body of literature on this 
topic is increasing at an exponential rate, much remains to be explored. We are just beginning to 
understand the many connections between metabolism and gene regulation in T cells (Kaelin and 
McKnight, 2013; Lu and Thompson, 2012; Ost and Pospisilik, 2015; Wang and Green, 2012). 
Acetyl-CoA and NAD+ generated from oxidative metabolism are used for histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) activity (Canto and Auwerx, 2011; 
Imai and Guarente, 2010; Wellen and Thompson, 2012). Protein acetylation is a reversible PTM 
that influences epigenetic changes mediated by HATs and HDACs and also controls the actions 
of transcription factors and molecular chaperones (Glozak et al., 2005). T-cell metabolic 
reprogramming during activation increases cytosolic NAD+ and citrate, the precursor of acetyl-
CoA, which may direct cell-fate decisions through protein acetylation (Berger et al., 1987). In 
agreement with this idea, lineage-specific cytokine-encoding genes that affect T-cell 
differentiation undergo dynamic changes in histone acetylation after antigen-driven stimulation 
(Avni et al., 2002; Fields et al., 2002). The actions of the transcription factor FoxP3 in directing 
Treg-cell development are controlled through opposing activities of the HATs p300 and TIP60, 
and the HDAC Sirtuin1 (Sirt1) (Beier et al., 2011; Li et al., 2007; Tao et al., 2007; van Loosdregt 
et al., 2010). Acetylation also affects the activity of circadian clock proteins, and reciprocally, 
the circadian acetylome has been found to regulate the epigenome and mitochondrial metabolic 
pathways (Koike et al., 2012; Lu and Thompson, 2012; Masri et al., 2013). Organisms rely on 
the cell autonomous transcription–translation oscillator loop managed by solar time to 
accommodate physiological changes brought about by the daily pattern of rest, activity, and 
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feeding (Curtis et al., 2014). The circadian clock also in part regulates Th17 cell development 
(Yu et al., 2013). Circadian rhythm controls nutrient acquisition and metabolic flux and it will be 
interesting to see how the body’s internal clock may connect to lymphocyte metabolism, 
regulation and function (Rey and Reddy, 2013). 
 
Intermediates from glucose catabolism can be converted into substrates that are needed to 
support cell growth and proliferation. Recent studies of one-carbon metabolism in cancer 
research involving the serine and glycine biosynthetic pathways may have implications for T-cell 
metabolism, given the many common features shared between activated T cells and proliferating 
cancer cells. Although the role of one-carbon metabolism in generating units for nucleic acid 
synthesis from folate has long been appreciated, more recently it was recognized that this 
pathway is an important source of NADPH to maintain redox balance and methyl groups for 
methylation (Fan et al., 2014; Locasale, 2013). For example, depletion of methylene 
tetrahydrofolate dehydrogenase (MTHFD) in cancer cells results in a decreased cellular 
NADPH/NADP+ ratio and increased oxidized glutathione, enhancing sensitivity to oxidative 
stress (Fan et al., 2014). Serine and glycine metabolism also have a vital role in cell survival 
under harsh environmental conditions of nutrient scarcity and hypoxia (Kim et al., 2015a). 
Tumors foster these kinds of conditions, but they are able to survive and function under these 
stressors. A recent study found that increased expression of mitochondrial serine 
hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC) confer a survival 
advantage for glioma cells by allowing them to lower their oxygen consumption and metabolize 
toxic molecules in the tumor microenvironment (Kim et al., 2015a). T cells also migrate and 
travel to sites of infection or tumors and must adapt to these hypoxic or nutrient-depleted 
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environments (Pearce et al., 2013). It remains to be explored whether these metabolic pathways 
support lymphocyte survival by similar mechanisms or have evolved to serve other purposes.  
 
Another area of interest is how substrate availability affects T-cell differentiation and their 
functional fate. Studies investigating the relationship between the gut microbiome and 
lymphocytes have found that metabolites produced by commensal bacteria have important 
implications for maintaining immune cell gastrointestinal homeostasis and defense against 
pathogens. Short chain fatty acids (SCFA) such as butyrate, acetate, and propionate produced by 
bacteria induce differentiation of colonic Treg cells (Furusawa et al., 2013; Smith et al., 2013) 
and also Th17 cells under certain conditions (Park et al., 2015). The vitamin A metabolite 
retinoic acid can synergize with TGF-β to stimulate Treg conversion (Coombes et al., 2007; 
Denning et al., 2007; Elias et al., 2008; Mucida et al., 2007; Sun et al., 2007). However, vitamin 
A metabolite deficiency also abrogates Th1 and Th17 cell immunity (Hall et al., 2011) and, more 
recently, was found to diminish type 3 innate lymphoid cells (ILC3s), but expand ILC2 cells 
(Spencer et al., 2014). Lymphocytes can also regulate whole body metabolism by affecting the 
tissues in which they reside. ILC2s can promote ‘beiging’ of white adipose tissue and therefore 
control caloric expenditure through secretion of methionine-enkephaline peptides (Brestoff et al., 
2015). Loss of insulin sensitivity due to inflammation of adipose tissue in obesity and type 2 
diabetes results in part from deficiencies in adipose tissue-specific Treg cell populations 
controlled by the transcriptional regulator PPAR-γ (Cipolletta et al., 2012; Feuerer et al., 2009). 
These are just a few examples of what remains to be explored in the interplay between 
lymphocytes, their environment, and metabolism. 
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In the development of novel therapeutics for the treatment of human disease, targeting T-cell 
metabolism provides a unique opportunity to manipulate T-cell function (O'Sullivan and Pearce, 
2015). For example, it has been demonstrated that compared to Th1 and Treg cells, Th17 cells 
have elevated pyruvate dehydrogenase kinase 1 (PDK1) expression, which promotes aerobic 
glycolysis through inhibition of pyruvate dehydrogenase (PDH). Inhibition of PDK1 using 
dichloroacetate (DCA) selectively impairs Th17 proliferation and survival and reduces T-cell 
mediated inflammation in models of inflammatory bowel disease and EAE (Gerriets et al., 
2015). Targeting trophic transporters on T cells may also provide a way in which to manipulate 
T-cell function through altering their nutrient uptake; for example JPH203, which inhibits amino 
acid transporter Slc7a5, could be used to inhibit inflammatory T cells without impairing Treg-
cell function (Hayashi et al., 2013; Sinclair et al., 2013). In the context of cancer, the 
development of adoptive cellular immunotherapies using in vitro expanded tumor infiltrating 
lymphocytes (TILs) could benefit from tailoring culture conditions to optimize TIL metabolism 
prior to transfer into the patient (Restifo et al., 2012). Exaggerated glycolysis and cell size 
resulting from in vitro expansion conditions, such as high glucose, can be detrimental to TIL 
survival and persistence in vivo. Strategies to limit glycolysis directly or suppress Akt activation 
in TILs have already shown promising results in this context (Crompton et al., 2015; Sukumar et 
al., 2013). Inhibiting glycolysis and oxidative metabolism with 2-DG and metformin may also 
hold therapeutic potential in other disease settings as highlighted by a recent study using models 
of system lupus erythematosus (Yin et al., 2015).  
 
It is apparent that many diverse processes integrate with lymphocyte signaling, gene regulation, 
and function to shape T-cell metabolism. Understanding the metabolic regulation that dictates T-
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cell fate and how nutrient availability and micro-environmental factors influence T-cell function 
will provide further insight into immune cell biology and could lead to new approaches to 
treating human diseases. 
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Figure 1. Metabolism drives the life cycle of T cells. 
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T cells engage specific metabolic pathways during the course of their development that underpin 
their differentiation and function. Naïve T cells mature and exit from the thymus primarily 
relying on OXPHOS for their metabolic needs, although they augment glycolytic metabolism 
during times of proliferation that follow TCR gene rearrangements. In secondary lymphoid 
organs, TCR ligation, costimulation, and growth factor cytokine signals induce clonal expansion 
and metabolic reprogramming of an antigen-specific T cell. This conversion to an activated 
effector T cell is marked by the engagement of aerobic glycolysis and increased OXPHOS 
activity. Glycolytic metabolism differentiates CD4 Th1, Th2, and Th17 effector cells (and 
possibly Tfh cells) from Treg cells. Promoting FAO and catabolic metabolism enhances Treg 
and memory T cell development (blue arrow). Memory T cells are a quiescent population of cells 
that primarily use OXPHOS, but both OXPHOS and glycolysis increase rapidly after antigen 
rechallenge and facilitate their recall responses. 
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Figure 2. Metabolic pathways that support T cells. 
 
  
 34 
ATP is the molecular currency of energy in the cell. It can be derived from glucose through two 
integrated pathways. The first of these, glycolysis (green), involves the enzymatic breakdown of 
glucose to pyruvate in the cytoplasm. The TCA cycle (orange) encompasses the second pathway 
where pyruvate is converted to acetyl-CoA in the mitochondria and shuttled through several 
enzymatic reactions to generate reducing equivalents to fuel OXPHOS (brown). Other substrates 
can also be metabolized in the TCA cycle, such as glutamine via glutaminolysis (purple) or fatty 
acids via β-oxidation (FAO) (gray). These connected biochemical pathways can also provide 
metabolic precursors for biosynthesis. Intermediates from glucose catabolism during glycolysis 
can shuttle through the pentose phosphate (dark blue) and serine biosynthesis pathways (red) to 
fuel nucleotide and amino acid production. Oxaloacetate from the TCA cycle can similarly be 
used to generate aspartate for use in nucleotide synthesis. Precursors for amino acid and 
nucleotide biosynthesis can be obtained from glutamine. Citrate from the TCA cycle can be 
exported from the mitochondria and converted to acetyl-CoA for FAS (light blue). ROS 
generated from the ETC during OXPHOS can also act as secondary signaling molecules. 
  
 35 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Metabolic Instruction of Immunity 
Commissioned publication for a 2017 issue of Cell 
 
  
 36 
Abstract 
 
Choices. Choices have consequences. Immune cells survey and migrate throughout the body and 
sometimes take residence in niche environments with distinct communities of cells, extracellular 
matrix, and nutrients that may differ from those in which they matured. Imbedded in immune 
cell physiology are metabolic pathways and metabolites that not only provide energy and 
substrates for growth and survival, but also instruct effector functions, differentiation, and gene 
expression. This review of immunometabolism will reference the most recent literature to cover 
the choices that environments impose on the metabolism and function of immune cells and 
highlight their consequences during homeostasis and disease. 
 
Introduction 
 
Cells of the immune system possess particular sets of skills – skills that are vital for host defense 
and tissue homeostasis, but also cause disease if not properly controlled – skills that make them 
altogether fairly peculiar. Unlike other cells in the body, immune cells possess the ability to 
respond to environmental signals and assume a wide variety of distinct functional fates. Immune 
cells can morph from dormant sentinels into pathogen killing machines, migrate from one tissue 
to another, modulate surface receptor expression, clonally expand, secrete copious amounts of 
effector molecules, or exert controlling effects over neighboring cells. After the burst of activity 
following an immune response, these specialized cells can die, creating space and limiting tissue 
damage in a particular environment, or return to resting states that allow them to persist for 
extended periods of time in readiness for a secondary response. 
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The activation, expansion, engagement of effector functions, and return to homeostasis of 
immune cells are intimately linked and dependent on dynamic changes in cellular metabolism. 
The utilization of particular metabolic pathways is controlled on one level by growth factors and 
nutrient availability dictated by competition between other interacting cells, and on another level 
by the exquisite balance of internal metabolites, reactive oxygen species (ROS), and reductive 
and oxidizing substrates. Studying immune cells, particularly lymphocytes and myeloid cells, has 
lent deep insight into how cells differentiate and coordinate their behaviors with metabolism 
under a wide array of settings.  
 
Leukocytes are also nomads and settlers. They migrate from the place where they develop to 
survey the entire body, and sometimes take up residence in tissues in which they did not 
originate. In doing so, they must adapt to an ecosystem comprised of unique cells, extracellular 
matrix, growth factors, oxygen, nutrients, and metabolites. How do they do this and what are the 
genetic, metabolic, and immunological consequences of these adaptations? In this review, we 
will explore the interactions between immune cells and the tissue environments they inhabit, how 
these impinge on their metabolism, how their metabolism instructs their function and fate, and 
how these relationships contribute to tissue homeostasis and disease pathology. The central 
concepts of immune cell metabolism have been covered extensively in several reviews (Buck et 
al., 2015; MacIver et al., 2013; O'Neill and Pearce, 2016; O'Neill et al., 2016; Pearce et al., 
2013), and thus will not be discussed at length here. 
 
  
 38 
The tumor microenvironment 
 
Recent breakthroughs in immunotherapy have shown that eliciting immune responses against 
multiple types of cancer can lead to considerably longer-lasting remissions, or in some cases 
complete regression of metastatic disease (Ribas, 2015). Although it is well known that cancer 
cells can evade immune recognition through “immunoediting”, the process by which antitumor 
immune responses, especially those from tumor infiltrating T lymphocytes (TILs), select for 
cancer cell clones that no longer express detectable tumor antigens (Vesely and Schreiber, 2013), 
the advent of effective cancer immunotherapies has shown that additional mechanisms of 
immunosuppression exist that limit or impair antitumor immunity. Thus, considerable efforts are 
underway to elucidate other mechanisms that restrain antitumor responses to develop new and 
more efficacious forms of immunotherapy.  
 
At the forefront of these mechanisms to consider is how immune cell metabolism, and thus 
immune cell function, is altered by the tumor microenvironment. Tumors are a major disturbance 
to tissue homeostasis, creating metabolically demanding environments that encroach on the 
metabolism and function of infiltrating immune and stromal cells. The unrestrained cell growth 
seen in cancer is often supported by aerobic glycolysis, the same metabolic pathway needed to 
fuel optimal effector functions in many immune cells (Pearce et al., 2013; Warburg, 1956; 
Warburg et al., 1958). At minimum, this similarity creates a competition for substrates between 
tumors and immune cells. The demand for nutrients, essential metabolites, and oxygen imposed 
by proliferative cancer cells, in combination with their immunosuppressive by-products, creates 
harsh environmental conditions in which immune cells must navigate and adapt (Figure 3). How 
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tumor and immune cells share or compete for resources in this environment, and how such 
relationships regulate antitumor immunity are important questions to address.  
 
Hypoxia 
When tumor growth exceeds the vasculature’s ability to fully perfuse the tumor 
microenvironment with oxygen, regions of hypoxia are established and induction of the hypoxia-
responsive transcription factor HIF-1α intensifies cancer cell glucose utilization and lactate 
release (Eales et al., 2016). Using 13C-labeled glucose, Hensley and colleagues traced the fate of 
glucose within healthy lung tissue and tumors of patients with non-small lung cell carcinoma and 
found that even within a single tumor, heterogeneity in glucose utilization exists (Hensley et al., 
2016). Lesser-perfused regions of the lung tumors were associated with higher glucose 
metabolism whereas higher-perfused regions could utilize circulating lactate, transported through 
monocarboxylate transporter 1 (MCT1), as an alternative TCA cycle substrate (Sonveaux et al., 
2008). Lactate metabolism in oxygenated cancer cells also increases glutaminolysis (Pérez-
Escuredo et al., 2015). How this metabolic heterogeneity in tumor cells relates to intratumoral 
immune cell function has not been well elucidated, but exposure of NK and T cells to high 
concentrations of lactate impairs their activation of the transcription factor NFAT and production 
of the cytokine IFN-γ (Brand et al., 2016). Lactic acid also disrupts T cell motility and causes 
loss of cytolytic function in CD8 T cells (Haas et al., 2015). Moreover, decreasing conversion of 
pyruvate to lactate by genetic targeting of lactate dehydrogenase A (LDHA) in tumors helps to 
restore T cell infiltration and function (Brand et al., 2016), linking lactate production to 
immunosuppression observed in the tumor microenvironment (Figure 3).  
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Lactate uptake by tumor-associated macrophages (TAMs) also stimulates tumor progression by 
inducing vascular endothelial growth factor (VEGF) and arginase I (Arg1) expression through 
HIF-1α (Colegio et al., 2014). Moreover, chronic VEGF signaling in hypoxic areas leads to 
elevated glycolysis in endothelial cells, resulting in excessive endothelial sprouting and abnormal 
leaky vasculature (Goveia et al., 2014). Interestingly, inhibition of REDD1, a hypoxia-induced 
inhibitor of mTOR, in TAMs increases their rates of glycolysis to a level that competes with 
neighboring endothelial cells for glucose and suppresses their angiogenic activity. This metabolic 
tug-of-war over glucose helps restore vascular integrity, improve oxygenation within the tumor, 
and prevent metastases (Wenes et al., 2016), providing an example of an intimate metabolic 
relationship that exists between cells in tumors. 
 
Hypoxia also has considerable effects on TIL function, proliferation, and migration (Vuillefroy 
de Silly et al., 2016). Increases in HIF-1α activity by culturing T cells in physiologic normoxia 
(~3-5% O2), genetic deletion of von Hippel-Lindau (VHL) factor, or inhibiting activity of the 
oxygen-sensing prolyl-hydroxylase (PHD) family of proteins, enhances CD8 T cell glycolysis 
and effector functions and promotes antitumor immunity (Clever et al., 2016; Doedens et al., 
2013; Finlay et al., 2012; Wang et al., 2011). HIF-1α is also needed for the production of the 
metabolite S-2-hydroxyglutarate (S-2HG), which can drive epigenetic remodeling in activated 
CD8 T cells and enhance IL-2 production and antitumor defenses (Tyrakis et al., 2016).  
 
Thus, one may expect that hypoxia would potentiate HIF-1α activity and TIL effector functions 
in tumors, however this is not what is observed. In addition to signals received from TIL IFN-γ 
(Noman et al., 2014), HIF-1α also induces the expression of the suppressive ligand PD-L1 in 
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tumor cells, TAMs, and myeloid-derived suppressor cells (MDSCs), and this can lead to TIL 
suppression via PD-1 (Figure 3). Moreover, recent work in both mouse and human tumors 
showed that CD8 TILs lose mitochondrial mass, membrane potential, and oxidative capacity, 
particularly within the most dysfunctional PD-1+ CD8 T cells (Scharping et al., 2016). The loss 
of mitochondrial function in TILs correlated with diminished expression of PPAR-gamma 
coactivator 1α (PGC1α) over time and a block in their proliferation and IFN-γ production. 
Perhaps severe hypoxia ultimately diminishes TIL effector functions. Indeed, respiratory 
supplementation of oxygen or treatment with metformin decreased intratumoral hypoxia and 
relieved several immunosuppressive features in the tumor microenvironment; the latter also 
served as an adjunct therapy that enhanced the antitumor effects of PD-1 blockade (Hatfield et 
al., 2015; Scharping et al., 2017). These findings suggest that remodeling the hypoxic tone in 
tumors may be an essential component to developing more efficacious forms of immunotherapy 
for patients.  
 
Nutrient alterations and competition within the tumor microenvironment 
Apart from hypoxia, the competition for nutrients and metabolites between tumor cells and 
infiltrating immune and stromal cells can be fierce, consequently influencing signal transduction, 
gene expression, and the metabolic activities of these neighboring cells. For example, tumor cells 
manipulate surrounding adipocytes to increase lipolysis to whet their appetite for fatty acids 
(Nieman et al., 2011). Cancer associated fibroblasts degrade tryptophan that not only starves 
immune cells in the local environment of an essential amino acid, but also leads to the 
production of the immunosuppressive metabolite kynurenine (Hsu et al., 2016). Moreover, 
glucose is a critical substrate for the antitumor functions of effector T cells and M1 macrophages, 
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which both require engagement of aerobic glycolysis for their activation and full effector 
functions (Buck et al., 2015; O'Neill and Pearce, 2016). Augmented aerobic glycolysis in cancer 
cells and endothelial cells places immune cells and their neighbors at odds (Figure 3). Glucose 
deprivation represses Ca2+ signaling, IFN-γ production, cytotoxicity, and motility in T cells and 
pro-inflammatory functions in macrophages (Cham et al., 2008; Chang et al., 2013; Chang et al., 
2015; Macintyre et al., 2014). Several recent studies have demonstrated that the glycolytic 
activities of cancer cells may restrict glucose utilization by TILs, thereby impairing antitumor 
immunity (Chang et al., 2015; Ho et al., 2015; Zhao et al., 2015). Increasing glycolysis rates of 
tumor cells through overexpression of the glycolytic enzyme hexokinase 2 (HK2) suppressed 
glucose-uptake and IFN-γ production in TILs and created more immunoevasive tumors (Chang 
et al., 2015; Ho et al., 2015). Zhao and colleagues found that glucose restriction imposed by 
ovarian cancer leaves microRNA repression of the methyltransferase EZH2 intact in CD8 T 
cells, reducing their survival and functional capacity (Zhao et al., 2015). Thus, tumor cells can 
selfishly coerce or outcompete neighboring cells for glucose to supply their own metabolic 
demands in a manner that simultaneously suppresses immune defenses.  
 
Amino acid deprivation in the tumor microenvironment serves as another metabolic checkpoint 
regulating antitumor immunity. Glutaminolysis in tumor cells is critical to replenish metabolites 
through anaplerotic reactions, which could result in competition for glutamine between tumor 
cells and TILs (Jin et al., 2015; Pérez-Escuredo et al., 2015). Glutamine controls mTOR 
activation in T cells and macrophages and is also a key substrate for protein O-GlcNAcylation 
and synthesis of S-2HG that regulate effector T cell function and differentiation (Sinclair et al., 
2013; Swamy et al., 2016; Tyrakis et al., 2016). TAMs, MDSCs, and tolerizing dendritic cells 
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(DCs) can suppress TILs through expression of essential amino acid (EAA)-degrading enzymes 
such as Arg1 and indoleamine-2,3-dioxygenase (IDO) (Figure 3) (Lee et al., 2002; Munn et al., 
2002; Rodriguez, 2004; Uyttenhove et al., 2003). Indeed, inhibitors of Arg1 and IDO are under 
investigation as therapeutic targets in clinical trials (Adams et al., 2015). Several recent studies 
have highlighted the critical roles of other amino acids such as arginine, serine, and glycine in 
driving T cell expansion and antitumor activity, but how the availability of these fluctuate within 
the tumor microenvironment is not clear (Geiger et al., 2016; Ma et al., 2017). Currently, a 
knowledge gap exists of how the availability of various nutrients and metabolites vary across 
tumor types, genotypes or even spatially within tumors to affect antitumor immune responses.  
 
Bioactive lipids, modified lipoproteins, and cholesterol metabolism within the tumor are also 
important mediators of immune cell function. Like macrophages in atherosclerotic plaques, DCs 
in the tumor can accumulate oxidized lipoproteins through scavenger receptor mediated 
internalization and formation of lipid droplets, which can ultimately impair their ability to cross-
present tumor antigens and activate T cells (Cubillos-Ruiz et al., 2015; Ramakrishnan et al., 
2014). Expression of lectin-type oxidized LDL receptor 1 (LOX-1) selectively marks MDSCs 
and oxidized lipid uptake and lipoprotein metabolism contributes to their T cell suppressive 
functions (Condamine et al., 2016). In addition, blocking cholesterol esterification in TILs by 
targeting ACAT1 pharmacologically or genetically increases intracellular levels of cholesterol 
and confers superior T cell responses in a model of melanoma (Yang et al., 2016). It is possible 
that as immune cells adapt to different tumor microenvironments and the limited availability of 
“immune stimulatory” nutrients, they become more dependent on alternative fuel sources (such 
as fats or lactate) that are less conducive to supporting antitumor effector functions. In summary, 
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more elaborate knowledge of these forms of metabolic cross talk or competition between cells 
within tumors is needed before one can begin to think about how to manipulate these 
relationships in a manner that alters tumor progression.  
 
Metabolic exhaustion in TILs and checkpoint blockade 
As TILs adapt to the tumor microenvironment, they progressively lose their ability to respond to 
T cell receptor (TCR) stimuli, produce effector cytokines, and proliferate – a process termed 
functional exhaustion or hyporesponsiveness. This is in part due to the upregulation of several 
inhibitory receptors like PD-1, LAG3, TIGIT, and CTLA-4 that desensitize T cells to tumor 
antigens (Wherry and Kurachi, 2015) (Figure 3). PD-1, its ligand PD-L1, and CTLA-4 are 
important checkpoints for T cells in tumors and the targets of a new and powerful class of cancer 
treatments that elicit effective and durable responses in patients across multiple cancer types 
(Ribas, 2015). Interestingly, both chronic exposure to antigen or environmental triggers such as 
glucose deprivation can upregulate PD-1 (Chang et al., 2013; Wherry and Kurachi, 2015). PD-1 
not only suppresses TCR, PI3K and mTOR signaling in T cells, but also dampens glycolysis and 
promotes fatty acid oxidation (FAO) – features that may enhance the accumulation of 
suppressive regulatory CD4 T (Treg) cells in tumors (Bengsch et al., 2016; Parry et al., 2005; 
Patsoukis et al., 2015). Indeed, blockade of PD-1 re-energizes anabolic metabolism and 
glycolysis in exhausted T cells in an mTORC1 dependent manner (Chang et al., 2015; Staron et 
al., 2014). This breathes caution into the types of drug combinations one may consider with α-
PD-1:PD-L1 blockade or other forms of immunotherapy. Metabolic interventions, such as the 
use of mTOR inhibitors, must be targeted specifically to avoid unintended compromises of 
immune cell function. The PD-1:PD-L1 axis may also directly affect the metabolic activity of 
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tumor cells (Figure 3). It was shown that PD-L1 expression correlated with the rates of 
glycolysis and the expression of glycolytic enzymes in those cells (Chang et al., 2015).  
Furthermore, checkpoint blockade antibodies including α-PD-L1 led to an increase in 
extracellular glucose in tumors in vivo that likely contributed to the improved TIL function and 
subsequent tumor regression observed. On this note, tumor cell-intrinsic PD-1 expression has 
also been observed that counter intuitively may increase intrinsic mTOR signaling and tumor 
growth (Kleffel et al., 2015). Collectively, these findings suggest there may be broader role of 
the PD-1:PD-L1 axis in cellular metabolism that extends beyond T cells. 
 
Improving the proportion of patients that respond to immunotherapy is an intense area of study, 
ranging from the search for biomarkers of response, target discovery, to testing new combination 
therapies. Likely, the most effective therapies will coordinately target co-inhibitory receptor to 
ligand interactions and restore a T cells’ ability to utilize metabolic substrates necessary to 
sustain their effector functions.  Seemingly paradoxical is the observation that dampening 
effector T cell differentiation by impairing glycolysis and boosting mitochondrial FAO and 
OXPHOS potentiates their survival and functional capacity (Buck et al., 2016; Sukumar et al., 
2013). Additionally, manipulating metabolic enzyme expression to help T cells adapt to 
metabolic perturbations in the tumor microenvironment may be other viable strategies (Clever et 
al., 2016; Doedens et al., 2013; Ho et al., 2015; Scharping et al., 2016), especially for adoptive 
cell therapy, a personalized form of cancer treatment that allows for the manipulation and 
expansion of a patient’s antitumor T cells prior to re-infusion (O'Sullivan and Pearce, 2015). As 
our capability to selectively reprogram T cell metabolism and reinvigorate tumor-specific T cells 
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improves, there is much promise to provide greater therapeutic benefits to more patients, 
especially to those with previously incurable cancers. 
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Figure 3. Metabolic tug-of-war within the tumor microenvironment. 
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The balance of nutrients and oxygen within the tumor microenvironment controls immune cell 
function. Glucose and amino acid consumption by tumor cells can outpace that of infiltrating 
immune cells, specifically depriving them of nutrients to fuel their effector function. Poorly 
perfused tumor regions drive hypoxia response programs in tumor cells, macrophages, and T 
cells. Increased HIF-1α activity in response to hypoxia or other mechanisms promotes glycolysis 
and increases concentrations of suppressive metabolites and acidification of the local 
environment. As a by-product of glycolysis, lactate concentration increases, which is 
coordinately utilized by tumor cells to fuel their metabolism, promotes macrophage polarization, 
and directly suppresses T cell function. The ability of T cells to target tumors is further limited 
by their upregulation of co-inhibitory receptors and engagement with their ligands on 
neighboring tumor cells and macrophages. As T cells progressively enter a dysfunctional state, 
their mitochondrial mass and oxidative capacity declines ultimately leading to their failure to 
meet bioenergetic demands to sustain effector functions and control tumor cell growth. 
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The gut environment 
 
While the tumor microenvironment is often depicted as nutrient restrictive, the mammalian 
gastrointestinal tract represents a metabolically rich and diverse tissue system. Its primary 
function is to digest and absorb nutrients with the aid of microbial species contained within the 
lumen. A single layer of epithelial cells is all that separates these commensal microbes from the 
rest of the body. The majority of intestinal epithelial cells (IECs) are absorptive enterocytes that 
digest and transfer nutrients, however additional specialized epithelial lineages exist with a 
diverse array of functions. For example, goblet and Paneth cells secrete mucins and antimicrobial 
peptides that fortify the barrier against potentially pathogenic microbes, microfold (M) and 
goblet cells assist in the transferring of luminal antigens across the epithelial barrier for sampling 
by mucosal DCs, and Tuft cells are important for sensing and responding to protozoa and 
helminths. Together with intestinal resident immune cells including innate lymphoid cells 
(ILCs), intraepithelial lymphocytes (IELs), helper T cells and B cells, a balancing act between 
barrier protection and microbial tolerance with surveillance and inflammation is maintained 
(Figure 4). While the relationship between gut commensal microbes and immune cell 
development and function and also how IECs interface with immune system regulation has 
recently been reviewed (Kurashima and Kiyono, 2017), we examine the unique constraints that 
this environment presents on cellular immunometabolism. 
 
While IECs control the intake of nutrients from the luminal environment of the gut, a recent 
study provides evidence that the way they are structured and uniquely placed controls their 
metabolic activity and function (Kaiko et al., 2016). The layer of epithelia in the small intestine 
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are organized into crypts and villi, which form invaginations that serve to optimize surface area 
whereby nutrients can be absorbed. At the base of the colonic crypt lie epithelial stem/progenitor 
cells that differentiate into specialized IECs as they migrate up the crypt-villus axis until they are 
eventually lost from the epithelial layer. This process of self-renewal from the crypt is 
continuous and therefore is a site of active proliferation (Kurashima and Kiyono, 2017). Kaiko, 
Ryu and colleagues screened microbiota derived products for their impact on intestinal epithelial 
progenitors and identified the short chain fatty acid (SCFA) butyrate as a potent inhibitor of 
intestinal stem cell proliferation at physiologic concentrations present within the lumen (Kaiko et 
al., 2016). They further found that differentiated colonocytes located at the forefront of the villi 
metabolized butyrate to fuel OXPHOS, thereby limiting its access to underlying progenitor cells, 
which do not readily utilize this substrate. Either removal of the ability to metabolize butyrate via 
deletion of acyl-CoA dehydrogenase or increased abundance of butyrate prevented the rapid 
regeneration of epithelial tissue after gut injury. Thus a combination of physical separation in the 
crypt and fermentation of butyrate by mature colonocytes protects the proliferating progenitor 
pool of IECs (Figure 4). 
 
 
B and Tfh cell metabolism 
Another unique structural feature of the gut are the Peyer’s patches, aggregates of gut associated 
lymphoid tissue (Reboldi and Cyster, 2016). Found in the small intestine, they represent a 
specialized lymphoid compartment continuously exposed to food- and microbiome-derived 
antigens. Due to this exposure, Peyer’s patches are rich in germinal centers (GCs), which are 
comprised of B, T, stromal, and follicular DCs. B cells segregate into zones where they undergo 
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cycles of proliferation and differentiation and compete for signals directing class switch 
recombination (CSR) and survival from T follicular helper (Tfh) cells, allowing further 
maturation of the antibody repertoire. 
 
Although the literature on B and Tfh cell metabolism is still developing, it has been shown that B 
cell activation induced by either α-IgM ligation or LPS increases Glut1 expression and glucose 
uptake downstream of PI3K and mTOR signaling (Caro-Maldonado et al., 2014; Doughty et al., 
2006; Jellusova and Rickert, 2016; Lee et al., 2013; Woodland et al., 2008). Glycolysis and 
OXPHOS are augmented as well as mitochondrial mass (Caro-Maldonado et al., 2014; Doughty 
et al., 2006; Dufort et al., 2007). Increased glucose acquisition also fuels de novo lipogenesis 
necessary for B cell proliferation and growth of their intracellular membranes. Inhibition of the 
fatty acid synthesis (FAS) enzyme ATP-citrate lyase in splenic B cells results in reduced 
expansion and expression of plasma cell differentiation markers (Dufort et al., 2014). Although 
apoptosis inducing factor (AIF) is required for T cell survival via electron transport chain (ETC) 
complex I function and respiration, AIF deficiency in B cells has no impact on their development 
or survival because of their reliance on glucose metabolism (Milasta et al., 2016). B cells 
cultured in galactose fail to expand unlike T cells, which can activate and proliferate in the 
presence of either galactose or glucose (Chang et al., 2013; Milasta et al., 2016). On the other 
hand, the transition to durable humoral immunity by long-lived plasma cells (LLPCs) was shown 
to be dependent on mitochondrial pyruvate import (Figure 4). Glucose supports antibody 
glycosylation, but LLPCs acquire more glucose than their short-lived counterparts and their 
long-term survival is dependent on their ability to siphon glucose-derived pyruvate into the 
mitochondria during times of metabolic stress (Lam et al., 2016).  
 52 
 
It is interesting to speculate that with the constant proliferation of GC B cells in the gut and the 
importance of glucose and glycolysis in activated plasma cells, access to glucose would become 
limiting for other cells that occupy this microniche. A few studies suggest that Tfh cells have 
evolved to be uniquely suited to survive under these constraints. It has been shown that Tfh cells 
have less mTORC1 activation and reduced glycolysis compared to Th1 cells (Ray et al., 2015). 
In part, this may be due to expression of their lineage defining transcription factor Bcl6, which 
can suppress glycolysis potentiated by c-Myc and HIF-1α (Johnston et al., 2009; Nurieva et al., 
2009; Oestreich et al., 2014). Consistent with this, overexpression of Bcl6 reduces glycolysis in 
T cells, and ablation of mTOR using shRNA favors Tfh cell development over Th1 cells in vivo 
after viral infection (Ray et al., 2015) (Figure 4). However, a more recent study using mice with 
conditional deletions of mTORC1 and mTORC2 via OX40 and CD4 cre recombinase observed a 
requirement of mTOR signaling in Tfh cell development and GC formation within Peyer’s 
patches (Zeng et al., 2016). The former applied retroviral mTOR shRNA, which requires T cells 
be fully activated prior to knockdown, while this more recent report used mice where mTOR was 
excised during T cell development or at the moment of T cell activation, which may explain the 
disparity between the studies. 
 
In addition to possibly limiting quantities of glucose substrate within GCs, these microniches 
contain areas of hypoxia, resulting in HIF-1α activation (Abbott et al., 2016; Cho et al., 2016). B 
cells placed under hypoxic conditions had reduced activation induced deaminase expression and 
subsequently underwent less CSR to the pro-inflammatory IgG2c isotype when cultured in 
conditions that promote IgG production (Cho et al., 2016). In contrast, B cells cultured in IgA-
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promoting conditions during hypoxia were unaffected, yielding comparable levels of IgA to cells 
kept at normoxia and highlighting how lymphocyte function may be fine-tuned to varying 
oxygen tension in tissues (Figure 4). B cells isolated from mice with constitutive activation of 
HIF-1α by deletion of its suppressor VHL had defects in IgG2c production, which was attributed 
to diminished mTORC1 activation. B cells from Raptor deficient heterozygotes also yielded 
fewer IgG antibodies (Cho et al., 2016). A separate study found that the mTOR inhibitor 
rapamycin dampens CSR, yielding the formation of lower affinity, more cross reactive B cell 
antibodies, which offered broad protection against heterosubtypic flu infection (Keating et al., 
2013).  Both mTORC1 and HIF-1α promote aerobic glycolysis (O'Neill and Pearce, 2016). 
However, the metabolic activities of the cells cultured under different isotype conditions while 
under hypoxia were not explored. Cytokines initiate CSR to distinct isotypes and signals derived 
from these growth factors might be responsible for the differences in metabolic signaling and 
suggest varying requirements to initiate metabolic programs and CSR in B cells. Secretion of 
IgA predominates the gut and is critical to maintaining barrier protection and bacterial 
homeostasis (Kurashima and Kiyono, 2017). The apparent stability of CSR to the IgA isotype 
under hypoxia and impaired pro-inflammatory IgG2c subtype might have evolved to ensure 
tolerance with the microbiome, while concurrently providing a stringent method of selection of 
antibodies produced during inflammatory responses to pathogen-derived antigens. 
 
Nutrients and immune signals in the gut 
The metabolic relationship between commensals and immune cells in the gut is further illustrated 
by the finding that SCFAs derived from the fermentation of dietary fiber by gut microbiota 
promote B cell metabolism and boost antibody responses in both mouse and human B cells (Kim 
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et al., 2016). Supplementation with dietary fiber or the SCFAs acetate, propionate, and butyrate 
increases intestinal IgA production, as well as systemic IgG during infection (Figure 4).  
Culturing B cells with SCFAs was shown to raise acetyl-CoA levels and increase mitochondrial 
mass, lipid content, and FAS leading to increased plasma cell differentiation and metabolic 
activity (Kim et al., 2016). Part of this phenotype could be attributed to histone deacetylase 
(HDAC) inhibition, an established effect of SCFA supplementation. 
 
In addition to their effects on B Cells, SCFAs have been found to promote the development and 
function of colonic Treg cells via induction of Foxp3 in a HDAC dependent manner (Arpaia et 
al., 2013; Furusawa et al., 2013; Smith et al., 2013) (Figure 4). Treg cells are critical to 
maintaining commensal tolerance by the immune system through suppression of aberrant T cell 
responses. Unlike other activated T helper subsets, Treg cells have been described to primarily 
rely on OXPHOS driven by FAO (Newton et al., 2016). However, signals downstream of TLR 
ligation can augment glycolysis and proliferation of Treg cells and reduce their ability to 
suppress T cell responses (Gerriets et al., 2016). Retroviral enforced expression of Foxp3 
promotes OXPHOS and dampens glucose uptake and glycolysis, whereas Treg cells transduced 
with Glut1 decreased Foxp3 expression after adoptive transfer in vivo and fail to suppress T cell-
mediated colitis in a model of inflammatory bowel disease. These findings suggest that during 
inflammation and microbial infection, Treg cells may temporarily lose their regulatory function 
to give way to robust T cell responses and participate as more conventional effector helper T 
cells. Increases in NaCl either from supplementation in vitro or diet in vivo inhibit the 
suppressive function of human Treg cells via serum/glucocorticoid-regulated kinase 1 (SGK1), 
which integrates signals from PI3K and mTORC2 to regulate sodium controlled signal 
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transduction (Hernandez et al., 2015). However, a study of human Treg cells found that the 
glycolytic enzyme enolase-1 was required for their suppressive activity through its control of 
Foxp3-E2 splice variants (De Rosa et al., 2015). Depending on environmental cues and 
metabolites, it appears that Treg cell metabolism can be modulated, affecting their function. 
 
As discussed, increases in SCFAs either from diet, infection, or exogenous treatment impinge on 
metabolic process including HDAC activation (Rooks and Garrett, 2016). A recent study 
suggests that activation of the HDAC sirtuin 1 (SIRT1) negatively impacts Th9 cell 
differentiation (Wang et al., 2016). The exposure of CD4 T cells to distinct cytokine cocktails 
differentiates them into separate helper lineages. However, perturbing metabolism also 
modulates CD4 T cell fate. A yin and yang relationship between Th17 and Treg cell 
differentiation has been established. Th17 cells are particularly glycolytic and depend on 
engagement of this pathway downstream of mTOR and HIF-1α activation. Dampening 
glycolysis through deletion of HIF-1α or with the inhibitor 2-DG in T cells impairs Th17 
development and instead promotes Treg cells, even under Th17-inducing culture conditions 
(Dang et al., 2011; Shi et al., 2011). Suppression of mTOR with rapamycin or genetic ablation 
also augments production of Treg cells (Delgoffe et al., 2009; Kopf et al., 2007), and 
pharmacological inhibition of de novo fatty acid synthesis prevents Th17 differentiation and 
instead enforces a Treg cell phenotype (Berod et al., 2014). 
 
Although the metabolic characteristics of other CD4 T cell subsets have been compared 
(Michalek et al., 2011), little was known about Th9 cell metabolism. Th9 cells are characterized 
by their ability to produce IL-9 and can be generated from naïve cells in culture using the 
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cytokines TGF-β and IL-4. They have implicated roles in autoimmunity, melanoma, and worm 
infections (Kaplan et al., 2015). Wang and colleagues found that Th9 cells are highly glycolytic, 
in part from their active suppression of SIRT1 expression via the kinase TAK1 (Wang et al., 
2016). SIRT1 was previously shown to negatively control HIF-1α as well as mTOR (Lim et al., 
2010; Liu et al., 2013). In line with this, Th9 cell development was augmented in SIRT1-
deficient T cells whereas retroviral enforced expression of SIRT1 or dampening of aerobic 
glycolysis by chemical or genetic means impaired Th9 cell differentiation (Wang et al., 2016). 
Th9, Th17, and Treg cells all share the cytokine TGF-β for their development, but then depend 
on additional cytokine signals for their eventual fates. Given their divergent metabolic 
phenotypes, as well as HDAC requirements, it would be interesting to explore further whether 
variances in intracellular levels of SCFA metabolites for example, might couple with 
environment signals to influence their eventual metabolic and development pathway.  
 
Apart from its affect on CD4 T cells, the SCFA acetate also has been shown to affect secondary 
recall responses from CD8 memory T cells (Balmer et al., 2016). Germ-free mice reconstituted 
with commensal microbes, or oral or systemic infection with bacterial species, elevated serum 
acetate concentrations. Memory T cells generated in vitro or in vivo cultured with acetate levels 
observed during these infections secreted more IFN-γ and augmented glycolysis after 
restimulation. Acetate can be quickly converted into acetyl-CoA, which can condense with 
oxaloacetate into citrate in the mitochondria to fuel the TCA cycle and OXPHOS, be used as a 
substrate for FAS, or participate in post translational modification (PTM) of proteins including 
histones (Pearce et al., 2013). Balmer and colleagues mechanistically tied their results to lysine 
acetylation of the glycolytic enzyme GAPDH. GAPDH activity has been shown to regulate T 
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cell production of IFN-γ (Chang et al., 2013; Gubser et al., 2013). Although the study 
demonstrated that the enzymatic activity of GAPDH was altered by acetylation of K217, whether 
this PTM was critical to acetate-dependent increases in IFN-γ protein was not explored. In a 
separate report, CD4 T cells deficient in LDHA expression had defects in IFN-γ production, 
which stemmed from widespread lack of acetylation of the Ifng locus (Peng et al., 2016). LDHA 
is the critical enzyme that defines aerobic glycolysis, converting pyruvate to lactate. Culturing 
cells in galactose impairs aerobic glycolysis, as galactose enters glycolysis through the Leloir 
pathway at a significantly lower rate than glucose (Bustamante and Pedersen, 1977), a result 
confirmed by tracing galactose metabolism in T cells (Chang et al., 2013). Reducing GADPH 
engagement from glycolysis in this fashion permits moonlighting function by this abundantly 
expressed protein. It was shown that GAPDH binds to the 3’UTR of AU-rich containing 
cytokine mRNAs, preventing their efficient translation (Chang et al., 2013). Peng and colleagues 
argue against GAPDH posttranscriptional control of T cell function during aerobic glycolysis 
deficiency because modification of the 3’UTR of Ifng did not rescue defects in cytokine 
production in their system. However as the authors demonstrated, LDHA-deficient cells have 
defects in Ifng mRNA production, whereas cells forced to respire in galactose remain as 
transcriptionally competent for Ifng as those cultured in glucose. Supplementation with the 
SCFA acetate rescued their epigenetic defect and cytokine production. These studies show that 
aerobic glycolysis regulates both transcriptional and translational functions in T cells. 
 
While products generated from the microbiome can modulate the metabolism of immune cells 
and shift the balance between tolerance and inflammation, there are hints that immune driven 
signals central to gut homeostasis may also mediate their effects through metabolic modulation. 
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One such example is the pleotropic anti-inflammatory cytokine IL-10. Most hematopoietic cells 
produce and sense IL-10 and its importance for maintaining tolerance with the intestinal 
microbiota is clearly evident from observations that IL-10 or IL-10R deficient mice develop 
spontaneous colitis (Kuhn et al., 1993; Spencer et al., 1998). IL-10R deficiency in macrophages 
is also sufficient to recapitulate onset of severe colitis in mice (Shouval et al., 2014; Zigmond et 
al., 2014). Further, mice with a myeloid cell-specific deficiency in STAT3, which is activated 
downstream of the IL-10R by JAK1, develop chronic enterocolitis as they age (Takeda et al., 
1999). In experiments that shed light on the importance of aerobic glycolysis engagement in DC 
activation, it was found that treatment of DCs with recombinant IL-10 blocked increases in their 
glycolytic rate after LPS stimulation (Krawczyk et al., 2010). Cells subjected to IL-10R blockade 
further upregulated glycolysis after activation compared to controls. It is tempting to speculate 
that one of the ways IL-10 might be anti-inflammatory is through inhibition of metabolic 
reprogramming to aerobic glycolysis during innate immune cell activation (Figure 4). 
Coincidentally, STAT3 was found to localize to mitochondria and interact with ETC complexes, 
which helped maintain efficient OXPHOS in the heart (Wegrzyn et al., 2009). Whether 
traditional cell surface cytokine-receptor signaling could modulate levels of mitochondrial 
STAT3 was not explored. Of interest, CD8 T cells with a conditional deletion of the IL-10R fail 
to form memory T cells (Laidlaw et al., 2015), which depend on FAO driven OXPHOS for their 
generation after infection (Cui et al., 2015; Pearce et al., 2009; van der Windt et al., 2012). 
 
The gut is one example of a tissue that presents distinct metabolic challenges for immune cells, 
which affect their steady state and protective versus inflammatory responses. Other examples, 
such as skin, provide the potential for commensal organisms to metabolically affect immune cell 
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function, a topic reviewed elsewhere (Hand et al., 2016).  The intestinal tract is constantly 
subject to fluctuations in diet and sometimes the intake of invasive pathogens can also deprive 
metabolic substrates from immune cells. The bacterium Salmonella typhimurium produces a 
putative type II asparaginase that depletes available asparagine needed for metabolic 
reprogramming of activated T cells via c-Myc and mTOR (Torres et al., 2016).  The use of 
asparaginase for acute lymphoblastic leukemia treatment highlights the potential for the 
depletion of extracellular arginine to significantly affect cellular function (DeBerardinis and 
Chandel, 2016).  Lack of dietary vitamin B1 decreases the number of naïve B cells in Peyer’s 
patches due to their dependence on this TCA cycle cofactor, while leaving IgA+ plasma cells 
intact in the lamina propria (Kunisawa et al., 2015). Although ILC metabolism has only recently 
been explored (Monticelli et al., 2016; Wilhelm et al., 2016), it was found that in settings of 
vitamin A deficiency, type 2 ILCs sustain their function via increased acquisition and utilization 
of fatty acids for FAO (Wilhelm et al., 2016) (Figure 4). The internal balance between 
polyunsaturated fats and saturated fatty acids can also determine the pathogenicity of Th17 cells; 
cells that help maintain mucosal barrier immunity and contribute to pathogen clearance (Wang et 
al., 2015a). Long chain fatty acids (LCFA) promote Th1 and Th17 cell polarization and mice fed 
with LCFA have exacerbated T cell-mediated autoimmune responses, whereas mice fed with 
SCFA are protected (Haghikia et al., 2015). If the internal lipidome of Th17 cells can alter their 
function from protective to inflammatory as well as their access to LCFA versus SCFA in the 
small intestine, it begs the question of how other tissue systems with a rich diversity of fat 
deposits and cells, such as the adipose tissue, modulate the metabolism and function of resident 
immune cells. 
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Figure 4. Models of metabolic relationships in the gastrointestinal tract  
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The gut serves as a direct interface with the outside world and the foods we consume. A single 
epithelial cell layer separates the contents of the intestinal lumen from the lamina propria where 
DCs, macrophages, ILCs, and T cells reside. Peyer’s patches are interspersed along the 
epithelium, which in addition to supporting sampling of luminal antigens by DCs and M cells, 
house germinal centers that maturate IgA-secreting B cells with Tfh cell help. B cells augment 
glycolysis upon activation and depend on pyruvate import via Mpc2 for longevity as long-lived 
plasma cells (LLPCs). Plasma cell hunger for glucose may restrict this nutrient from Tfh cells, 
however Tfh cells downregulate glycolysis in response to expression of their lineage defining 
transcription factor. In addition, GCs contain areas of hypoxia that impinge on B cell function 
like class switch recombination (CSR). Commensal bacteria produce metabolites such as short 
chain fatty acids (SCFAs) from the fermentation of dietary fiber, which influence B cell 
metabolism and promote IgA secretion. The presence of SCFAs and vitamins support 
maintenance of barrier function by promoting the development and survival of Tregs and ILCs, 
respectively. Homeostatic signals secreted by gut resident immune cells (e.g. IL-10) may also 
modulate metabolism and therefore control their activation state. 
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Restructuring of intracellular metabolism 
 
Thus far, we have scrutinized some of the extracellular environmental factors, such as substrate 
availability, that influence immune cell metabolism and function. However, other more cell-
intrinsic processes determine the balance in metabolic pathway usage and subsequent immune 
response. Termed “restructuring of intracellular metabolism” here, these internal influences 
range from cytoskeletal and organelle structural remodeling to metabolite and redox balance 
(Figure 5).  
 
Cytoskeleton and asymmetric cell division 
Perhaps one of the most fundamental ways that cellular metabolism is altered in response to 
external stimuli is through gross structural changes in intracellular architecture. In an elegant 
dissection of PI3K signaling in epithelial cells, Hu and colleagues found cytoskeletal dynamics 
and glycolysis to be uniquely intertwined (Hu et al., 2016). The authors showed that addition of 
growth factors or insulin activated Rac downstream of PI3K, causing a disruption of the actin 
cytoskeleton. Loss of this structural integrity released bound aldolase from filamentous F-actin, 
increasing its catalytic activity. Chemical and genetic inhibition of PI3K, Rac, or actin dynamics 
modulated glycolysis via mobilization of aldolase (Figure 5). It will be interesting in future 
studies to explore how other glycolytic enzymes or even the mitochondria in immune cells 
restructure their metabolic activity through changes in cytoskeletal morphology in response to 
growth factor or pathogen-derived signals, especially since directed cellular migration is such an 
integral feature of how the disseminated immune system can focus its attention on points of 
infection or damage. On a related note, two complementary studies have found that in response 
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to activation by DCs, lymphocytes asymmetrically partition the metabolic regulators c-Myc and 
mTORC1 during the first cell division (Pollizzi et al., 2016; Verbist et al., 2016). This 
distribution event determines their eventual destiny wherein the daughter cell that inherits high c-
Myc expression and mTORC1 activity greatly augments glycolysis and undergoes higher rates of 
proliferation during a primary immune response and the other daughter cell maintains the 
metabolic profile of a memory T cell with increased persistence and secondary response 
capability. The patterning of Myc expression at the inception of the proliferative burst following 
activation also regulates a T cell’s capacity to sustain cellular division (Heinzel et al., 2016). 
 
Redox balance and mitochondrial dynamics 
The ability to maintain internal metabolite balance is also crucial for supporting the equilibrium 
of reductive and oxidizing equivalents such as NAD+/NADH and FAD/FADH2, which 
participate in redox reactions that release energy from the oxidation of substrates. Two recent 
back-to-back studies demonstrate a requirement for the synthesis of aspartate to balance redox 
that may have implications for highly proliferative lymphocytes, such as B and T cells (Birsoy et 
al., 2015; Sullivan et al., 2015). For about 20 years, it has been known that cells lacking a 
functional ETC possess a defect in proliferation that can be rescued by exogenous pyruvate 
(King and Attardi, 1989). However, how pyruvate accomplishes this feat remained untested. In 
the absence of a functional ETC, presumably NADH produced from cellular metabolism cannot 
be adequately oxidized. Sullivan and colleagues hypothesized that pyruvate may act as a 
surrogate electron acceptor to restore redox balance by generating NAD+ during its conversion to 
lactate. Indeed, when they added alternative substrates that also result in the oxidation of NADH, 
such as α-ketobutyrate, proliferation of cells with impaired ETC function was restored. Birsoy 
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and colleagues identified GOT1 through a CRISPR-Cas9 genetic screen as a critical factor for 
Jurkat leukemic T cell viability during ETC inhibition (Birsoy et al., 2015). Ultimately both 
studies recognized that aspartate, produced via GOT1, to be a critical metabolite for cells to 
expand and grow. When the ETC is dysfunctional, electron acceptors become limiting and 
aspartate synthesis is impaired that results in a block in cellular proliferation. 
 
As seen above, genetic selection or chemical impairment of the ETC perturbs redox balance, but 
a closer examination of mitochondrial dynamics in T cells suggests that physiologic restructuring 
of the mitochondria during an immune response also generates changes in redox flow that 
mediate metabolic pathway choice during activation and quiescence. Activation initiated by TCR 
ligation and binding with costimulatory molecules metabolically reprograms T cells for rapid 
anabolic growth and biomass accumulation. Concomitantly, mitochondria undergo biogenesis 
and take on a grossly punctate and dispersed morphology with expanded cristae junctions and 
augment aerobic glycolysis and OXPHOS (Buck et al., 2016; Ron-Harel et al., 2016). During 
this process, the mitochondrial proteome remodels itself to increase mitochondrial one-carbon 
metabolism. Knockdown of SHMT2, the first enzyme in this pathway, impairs CD4 T cell 
survival and proliferation in vivo (Ron-Harel et al., 2016). It has also been observed that effector 
and memory T cells have morphologically distinct mitochondria. Effector T cells have more 
“fissed” mitochondria whereas memory T cells have more “fused” mitochondrial networks with 
tight cristae suggesting a requirement for mitochondrial fusion in memory T cell metabolism and 
homeostasis. Consistent with this observation, antigen-specific T cells lacking the inner 
mitochondrial membrane fusion protein Opa1 fail to generate memory T cells after bacterial 
infection and have impaired survival in vitro (Buck et al., 2016). The activation, proliferation, 
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and function of Opa1 deficient effector T cells however, remain intact. Opa1 KO T cells have 
augmented rates of glycolysis and possess mitochondria with diminished OXPHOS efficiency 
and malformed cristae compared to controls. We found that in quiescent T cells, such as naïve 
and memory T cells, mitochondrial fusion ensured tight cristae associations that allowed for the 
ETC to function efficiently. On the other hand, mitochondrial fission directed cristae expansion 
during immune cell activation physically separated ETC complexes and decreased ETC 
efficiency, thereby disrupting cellular redox balance. In order to correct this redox imbalance, 
cells exported lactate from pyruvate conversion and in doing so, supported their commitment to 
aerobic glycolysis. These data suggest a model whereby the structural remodeling of 
mitochondria can signal the engagement of a particular metabolic pathway (Figure 5). 
 
Tight associations of mitochondrial cristae result in dense packing of ETC complexes, which 
have been found to associate in specialized configurations termed respiratory supercomplexes or 
respirasomes. Supercomplexes facilitate efficient transfer of electrons and minimize proton leak 
during ATP production (Cogliati et al., 2013). Research into this area is still growing, but a 
couple of studies have highlighted their contributions to immune responses. CD8 T cells express 
high levels of methylation-controlled J protein (MCJ), a member of the DnaJ family of 
chaperones (Champagne et al., 2016). MCJ localizes to the inner membrane of mitochondria and 
associates with complex I of the ETC. By doing so, it negatively regulates the assembly of 
complex I into supercomplexes. MCJ deficiency was found to enhance naïve and activated CD8 
T cell OXPHOS and a unique attribute was its role in the secretion, but not the translation, of 
effector cytokines (Champagne et al., 2016). Increased respiration efficiency improved the 
survival of the MCJ KO effector T cells, which also induced superior protective immunity 
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against viral challenge. Boosting oxidative capacity through enforcement of mitochondrial fusion 
also extends the survival and function of CD8 T cells in vivo (Buck et al., 2016). A separate 
study in myeloid cells found that TLR and inflammasome dependent bacterial recognition by 
macrophages induces a transient decrease of complex I respirasome assembly while enhancing 
complex II activity (Garaude et al., 2016). Inhibition of complex II (a.k.a. SDH – succinate 
dehydrogenase) in vivo disrupted production of IL-1β after infectious challenge while enhancing 
levels of the anti-inflammatory cytokine IL-10.  
 
Itaconate and ROS 
In relation to the role of SDH in macrophage cytokine production, a key example of an 
intracellular metabolite impinging on immune cell metabolism and response outcome is provided 
by itaconate. A comprehensive description of its discovery as an antimicrobial metabolite and 
modulator of immune cell bioenergetics has been reviewed recently (Luan and Medzhitov, 
2016). Upon activation, downstream of inflammatory stimuli such as TLR signaling, 
macrophages increase their internal concentrations of the metabolite itaconate by conversion of 
TCA cycle derived aconitate via the mitochondria-associated enzyme immunoresponsive gene 1 
(Irg1). Itaconate in turn competitively inhibits SDH function, resulting in succinate accumulation 
(Lampropoulou et al., 2016). Itaconate can also impair OXPHOS in a dose dependent manner 
(Cordes et al., 2016). Therefore, production of itaconate may necessitate the switch to aerobic 
glycolysis that occurs in myeloid cells after LPS stimulation by introducing a brake in the TCA 
cycle and ETC through SDH inhibition. However the situation is a bit more complicated (Figure 
5). Inflammatory cytokine production from activated myeloid cells is also coupled to 
commitment to ATP generation via aerobic glycolysis (O'Neill and Pearce, 2016). Exogenous 
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treatment with itaconate inhibits production of IL-1β, IL-6, IL-12, and ROS in response to 
inflammatory signals, while Irg1 deficient macrophages have increased inflammatory cytokine 
output (Lampropoulou et al., 2016). Irg1 KO cells have intact SDH activity and their hyper 
inflammatory phenotype agrees with a recent study demonstrating a requirement for SDH 
dependent IL-1β generation in LPS activated macrophages (Mills et al., 2016). Mills, Kelly and 
colleagues propose a model whereby IL-1β production is dependent on ROS generated from the 
oxidation of accumulated succinate that is driven by reverse electron transport (RET) from intact 
SDH. This builds from a previous report demonstrating that glutamine dependent succinate 
accumulation after LPS stimulation via glutamine-dependent anarplerosis and the γ-aminobutyric 
acid shunt pathway is important for augmenting glycolysis through HIF-1α stabilization and IL-
1β production from macrophages (Tannahill et al., 2013). However, Lampropoulou and 
colleagues describe succinate accumulation driven by itaconate inhibition of SDH. One possible 
explanation that unifies these observations is that initial signals downstream of TLR activation 
drive succinate production from glutamine to initiate ROS and generate IL-1β. Itaconate, later 
accumulates as Irg1 levels increase and feeds back on SDH to inhibit its activity and sets a 
threshold for inflammatory cytokine production (Luan and Medzhitov, 2016). In doing so, both 
processes may also initiate and sustain myeloid cell commitment to aerobic glycolysis. 
 
The generation of mitochondrial-derived ROS has been shown to be important for macrophage 
activation and inflammatory cytokine production and also critical for the activation and 
expansion of antigen-specific T cells (Mills et al., 2016; Sena et al., 2013; Tannahill et al., 2013). 
However, immune cells can generate ROS from other intracellular compartments apart from the 
mitochondrial ETC. Cellular superoxide anions can be released from the NADPH oxidase 
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(NOX), which assembles on the phagolysosome to aid in the destruction of ingested 
microorganisms. ROS derived from NOX has been previously shown to be critical for the 
activation of the NLRP3 inflammasome (Abais et al., 2015). However, a study from Moon and 
colleagues extends a role for NOX4 in the activation of the NLRP3 inflammasome through its 
modulation of FAO (Moon et al., 2016). NOX4 deficient mouse and human macrophages 
stimulated in vitro with ATP, nigericin, or silica had impaired caspase-1 activation and 
subsequent IL-1β and IL-18 maturation, although TNF-α production remained intact. 
Inflammasome activation was also diminished in NOX4 KO mice after S. pneumoniae challenge. 
This defect was identified as an inability of NOX4 deficient cells to augment Cpt1a dependent 
FAO during inflammasome activation.  Consistent with this observation, Cpt1a deficient 
macrophages were unable to activate the NLPR3 inflammasome, but enforced expression of 
Cpt1a in NOX4 KO macrophages rescued inflammasome activation and cytokine release 
(Figure 5). However, exactly how NOX4 regulates Cpt1a protein levels and FAO is unresolved.  
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Figure 5. Restructuring of intracellular architecture and metabolism. 
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Immune cell function is a product of their metabolic state. Growth factor signaling, actin 
rearrangement, and glucose metabolism are closely intertwined. Actin-bound aldolase can be 
freed from the cytoskeleton downstream of growth factor signaling to mediate glycolysis. 
Engagement of this pathway is central to the activation and downstream effector functions of 
DCs, M1 macrophages, and T cells. T cells can dynamically restructure their mitochondria 
through processes like mitochondrial fission and fusion to signal changes in metabolism and to 
promote long-term survival as they transition to memory cells. Inflammatory signals repurpose 
TCA cycle enzymes and metabolic intermediates such as itaconate, succinate, and processes like 
FAO to serve as internal signals that modulate ROS production, inflammasome activation, and 
cytokine production. 
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Outlook 
 
Immunology for some time became a field that sought reductionist approaches to simplify a 
complex network of cells. Out of necessity, immunologists had to speak a common language or 
jargon that often excluded scientists in other disciplines. After many decades of hard work, great 
strides have been made in our understanding of the immune system and now immunologists are 
better equipped to cross over into other disciplines. It is this ‘take a step back and look’ approach 
that has led a number of laboratories to focus on metabolism and how this affects the immune 
system as well as its greater impact in tissue physiology. 
  
It is obvious to most biologists that metabolism is integrated into every cellular process and fate 
decision. After all, everything must eat to survive. However, what is perhaps less appreciated is 
that the immune system is like a liquid organ unto itself.  At their inception, immune cells are 
poised to respond to unknown stimuli, nutrients, pathogens and are akin to special agents with 
contingency plans, ready to respond to one disaster scenario after another, or may be relegated to 
pushing paperwork at the office maintaining the status quo. We have only highlighted some 
examples of the complexity of the situations and environments that immune cells face that 
provide various metabolic instructional cues throughout this review. This ability to rapidly 
change and adapt at any given second means that immune cells must intimately integrate their 
cellular metabolism in a way that most other organ and cell systems in the body do not have to, 
which we hope this review has shown and inspires research into many questions that remain to 
be explored. Coupling the unique benefits of studying immunometabolism is the added bonus of 
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the enormous clinical relevance of these cells in human health and disease. First defining and 
then exploiting their unique metabolism may continue to yield new targets for therapy. 
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Chapter 3: Materials and Methods 
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Mice and immunizations  
C57BL/6, C57BL/6 CD45.1, C57BL/6 CD90.1, photo-activatable mitochondria (PhAM), and 
major histocompatibility complex (MHC) class I-restricted OVA specific TCR OT-I transgenic 
mice were purchased from The Jackson Laboratory. Mfn1 and Mfn2 conditional floxed mice 
were obtained from Dr. David C. Chan (California Institute of Technology, Pasadena, CA). 
Opa1 conditional floxed mice were obtained from Dr. Hiromi Sesaki (Johns Hopkins University 
School of Medicine, Baltimore, MD). All conditional floxed mice were crossed to OT-I CD4 Cre 
transgenic mice to generate OT-I Mfn1F/F CD4 Cre, OT-I Mfn2F/F CD4 Cre, and OT-I Opa1F/F 
CD4 Cre mice. All mice were bred and maintained under specific pathogen free conditions under 
protocols approved by the AAALAC accredited Animal Studies Committee of Washington 
University School of Medicine, St. Louis, MO USA and the Animal Welfare Committee of the 
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. Age matched mice 
were injected intraperitoneally (i.p.) or intravenously (i.v.) as indicated with a sublethal dose of 
1x106 colony forming units (CFU) of recombinant Listeria monocytogenes expressing OVA 
deleted for actA (LmOVA) for primary immunizations and challenged with 5x107 CFU for 
secondary immunizations. For tumor experiments, 1x106 EL4 lymphoma cells expressing OVA 
(EL4-OVA) were injected subcutaneously (s.c.) into the right flank of mice. 
 
Cell culture and drug treatments  
OT-I splenocytes were activated with OVA-peptide (SIINFEKL, New England Peptide) and IL-2 
(100 U/mL) for 3 days and subsequently cultured in the presence of either IL-2 or IL-15 (10 
ng/mL) for an additional 3 days in TCM (RPMI 1640 media supplemented with 10% FCS, 2 mM 
L-glutamine, 100 U/mL penicillin/streptomycin, and 55 µM β-mercaptoethanol). For drug 
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treatment experiments, vehicle control (DMSO) or 10 µM Mdivi-1 + 20 µM M1 (Sigma) were 
added to cultures daily starting on day 3. For in vitro survival assays, cells were activated for 3 
days as described, then cultured in either IL-2 at 5x104 cells/mL or IL-15 at 1x105 cells/mL in 96 
well round bottom plates. Survival was analyzed by 7AAD exclusion using flow cytometry. 
Bone marrow cells were differentiated for 7 days into BM-Macs by culturing in complete 
medium (RPMI 1640 supplemented with 10% FBS, 100 U/mL penicillin/streptomycin, 2 mM L-
glutamine) with 20 ng/mL mouse macrophage colony-stimulating factor (M-CSF; PeproTech) or 
into BM-DCs using 20 ng/mL granulocyte-macrophage colony-stimulating factor (GM-CSF; 
PeproTech). BM-Macs and BM-DCs were stimulated using 20 ng/mL LPS (Sigma), 50 ng/mL 
IFN-γ (R&D Systems), or 20 ng/mL IL-4 (PeproTech). BM-DCs were cultured in 5 ng/mL GM-
CSF during stimulation experiments.  
 
Flow cytometry and spinning disk confocal microscopy  
Fluorochrome-conjugated monoclonal antibodies were purchased from eBioscience, BD 
Pharmingen, or Biolegend and staining performed as previously described (Chang et al., 2015). 
OVA-specific CD8+ T cells from spleen, lymph node, or blood were quantified by direct staining 
with H2-KbOVA257-264 (KbOVA) MHC-peptide tetramers. MitoTracker, TMRM, CMxROS, 
MitoSOX, and Hoechst staining was performed according to the manufacturer’s instructions 
(Life Technologies). Nos2 protein levels in BM-Macs were quantified after fixation and 
permeabilization using the transcription factor staining buffer set (eBioscience) and a directly 
conjugated antibody against Nos2 (clone CXNFT, eBioscience). Cells were collected on FACS 
Calibur, Canto II, LSR II, and Fortressa flow cytometers (BD Biosciences) and analyzed using 
FlowJo (TreeStar) software. Cells were sorted using a FACS Aria II. Cells were imaged live on 
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glass bottom dishes coated with fibronectin or poly-D-lysine (Sigma) in TCM containing IL-2 or 
IL-15 (MatTek) using a LSM 510 META confocal scanning microscope (Zeiss), an Olympus 
Confocal Microscope FV1000, or a Zeiss spinning disk confocal with an Evolve (EMCCD) 
camera. Cells were kept in a humidified incubation chamber at 37°C with 5% CO2 during image 
collection. Images were deconvolved and analyzed using ImageJ (NIH). Brightness and contrast 
were adjusted in Adobe Photoshop CS.  
 
Transmission electron microscopy  
Cells were fixed in 2% paraformaldehyde, 2.5% glutaraldehyde in 100 mM sodium cocodylate 
containing 0.05% malachite green. Following fixation, samples were washed in cocodylate 
buffer and post fixed in 1% osmium tetroxide. After extensive washing in H2O, samples were 
stained with 1% aqueous uranyl acetate for 1 hour and washed again. Samples were dehydrated 
in ethanol and embedded in Eponate 12 resin (Ted Pella). Cut sections were stained with uranyl 
acetate and lead citrate and then imaged using a JOEL 1200 EX transmission electron 
microscope equipped with an 8 MP ATMP digital camera (Advanced Microscopy Techniques).  
 
Metabolism assays  
Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured in 
XF media (non-buffered RPMI 1640 containing 25 mM glucose, 2mM L-glutamine, and 1 mM  
sodium pyruvate) under basal conditions and in response to 200 µM etomoxir (Tocris), 1 µM 
oligomycin, 1.5 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP) and 100 nM rotenone + 1 
µM antimycin A, or 50 ng/mL phorbol 12-myristate 13-acetate (PMA) + 500 ng/mL ionomycin 
(all Sigma) using a 96 well XF or XFe Extracellular Flux Analyzer (EFA) (Seahorse Bioscience) 
 77 
(van der Windt et al., 2016). For mitochondrial fission inhibition experiments, cells were plated 
in XF media containing 10 µM Mdivi-1 or vehicle control (DMSO), followed by injection into 
port A with XF media, αCD3/CD28- conjugated beads (1 bead/cell; Dynabeads), or 20 ng/mL 
LPS ± 50 ng/mL IFN-γ.  
 
Glucose tracing  
Cells were activated with OVA peptide and cultured in glucose free TCM (prepared with 
dialyzed FBS) supplemented with 11 mM glucose. On day 3 of culture, cells were washed and 
cultured overnight in TCM replaced with 11 mM D-[1,213C] labeled glucose. For harvest, cells 
were rinsed with cold 150    mM ammonium acetate (NH4AcO), and metabolites extracted using 
1.2 mL of 80% MeOH kept on dry ice. 10 nM norvaline (internal standard) was added. 
Following mixing and centrifugation, the supernatant was collected, transferred into glass vials 
and dried via centrifugal evaporation. Metabolites were resuspended in 50    µL 70% ACN and 
5    µL of this solution used for mass spectrometer-based analysis performed on a Q Exactive 
(Thermo Scientific) coupled to an UltiMate 3000RSLC (Thermo Scientific) UHPLC system. 
Mobile phase A was 5    mM NH4AcO, pH 9.9, B was ACN, and the separation achieved on a 
Luna 3u NH2 100A (150 × 2.0    mm) (Phenomenex) column. The flow was kept at 200    µL/min, 
and the gradient was from 15% A to 95% A in 18    min, followed by an isocratic step for 9    min 
and re-equilibration for 7    min. Metabolites we detected and quantified as area under the curve 
(AUC) based on retention time and accurate mass (≤ 3    p.p.m.) using TraceFinder 3.3 (Thermo 
Scientific) software.  
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Adoptive transfers  
For in vivo memory T cell experiments, ≤1x104 OT-I+ CD8+ cells/mouse from donor splenocytes 
were transferred intravenously (i.v.) into congenic recipient mice. Blood samples or spleens were 
collected at indicated time points and analyzed by flow cytometry. For in vivo survival 
experiments, 1-2x106 day 6 IL-2 TE treated cells/mouse were injected i.v. into naïve C57BL/6 
mice. Cells were recovered two days later from the spleen or lymph nodes and analyzed by flow 
cytometry or isolated from spleens >3 weeks 6 days after LmOVA infection. For adoptive 
cellular immunotherapy experiments, 1-5x106 day 6 IL-2 TE treated cells/mouse were injected 
i.v. into previously EL4-OVA tumor inoculated mice and measured for tumor volume growth.  
 
RT-PCR and western blotting  
RNA isolations were done by using the RNeasy kit (Qiagen) and single-strand cDNA was 
synthesized using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). 
Genomic DNA was extracted using the QIAamp DNA micro kit (Qiagen) to determine 
mtDNA/nDNA ratios. All RT-PCR was performed with Taqman primers using an Applied 
Biosystems 7000 sequence detection system. The expression levels of mRNA were normalized 
to the expression of a housekeeping gene (β-actin). For western blot analyses, cells were washed 
with ice cold PBS and lysed in 1x lysis buffer (Cell Signaling Technologies) supplemented with 
1 mM PMSF. Samples were freeze-thawed 3 times and centrifuged at 20,000xg for 10 min at 
4°C. Cleared protein lysate was denatured with LDS loading buffer for 10 min at 70°C. For 
native lysis, cells were resuspended in native lysis buffer (Life Technologies), supplemented 
with increasing percentages of digitonin, MgCl, and micrococcal nuclease. After nuclease 
incubation at RT for 1h, lysates were cleared by centrifugation at 20,000xg for 30 min at 4°C. 
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For mitochondrial membrane solubilization analyses, both the cleared supernatant and pellet 
were denatured with LDS loading buffer for 10 min at 70°C. Samples were run on precast 4-12% 
bis-tris protein gels (Life Technologies). Proteins were transferred onto nitrocellulose 
membranes using the iBLOT 2 system (Life Technologies). Membranes were blocked with 5% 
w/v milk and 0.1% Tween-20 in TBS and incubated with the appropriate antibodies in 5% w/v 
BSA in TBS with 0.1% Tween-20 overnight at 4°C. The following antibodies were used: Opa1 
(BD), rodent OXPHOS complex proteins cocktail (Abcam), Calnexin (Santa Cruz), and β-Actin, 
Mfn2, Drp1, Drp1pS616 (Cell Signaling Technologies). All primary antibody incubations were 
followed by incubation with secondary HRP-conjugated antibody (Pierce) in 5% milk and 0.1% 
Tween-20 in TBS and visualized using SuperSignal West Pico or femto Chemiluminescent 
Substrate (Pierce) on Biomax MR film (Kodak).  
 
Retroviral transduction  
Activated OT-I splenocytes were transduced with control (empty vector) or Mfn1, Mfn2, Opa1 
expressing retrovirus by centrifugation for 90 minutes in media containing hexadimethrine 
bromide (8 µg/mL; Sigma) and IL-2 (100 U/mL). GFP or human CD8 were markers for 
retroviral expression.  
 
Cytotoxicity assay  
EL4-OVA tumor cells were pre-treated with 100 U/mL murine IFN-γ for 24 hours before use. To 
generate target cells, 1x106 tumor cells were labeled with 0.5 µM Cell Proliferation Dye e670 
(eBioscience) in PBS for 8 minutes at room temperature, washed twice with PBS and 10,000 
cells were seeded per well in 96-well round bottom plates. IL-2 TE cells treated with DMSO or 
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M1+Mdivi-1 were co-cultured with target cells at the indicated effector/target cell ratios and 
incubated for 12 hours at 37°C in 5% CO2. To generate reference cells, 1x106 tumor cells were 
labeled with 5 µM Cell Proliferation Dye e670 in PBS and incubated on ice. 10,000 reference 
cells were added before cells were stained with Po-ProTM-1 dead cell staining dye (Life 
Technologies). IL-2 TE cell killing efficiency was analyzed by flow cytometry and data defined 
as percentage of live cells normalized to reference cells.  
 
Statistical analysis  
Comparisons for two groups were calculated using unpaired two-tailed student’s t-tests, 
comparisons for more than two groups were calculated using one-way ANOVA followed by 
Bonferroni’s multiple comparison tests. Comparisons over time were calculated using two-way 
ANOVA followed by Bonferroni’s multiple comparison tests.  
  
 81 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Mitochondrial Dynamics Controls T Cell Fate Through Metabolic 
Programming 
Published in the June 30th, 2016 issue of Cell 
 82 
Introduction 
 
T cells are important mediators of protective immunity against pathogens and cancer and have 
several unique properties, not least of which is their ability to proliferate at a rate arguably unlike 
any other cell in an adult organism.  In this regard, one naïve T cell can clonally expand into 
millions of ‘armed’ TE cells in just a few days (Williams and Bevan, 2007). Concomitant with T 
cell activation is the engagement of Warburg metabolism, a metabolic phenotype shared by 
cancer cells and unicellular organisms (Fox et al., 2005; Vander Heiden et al., 2009). Once the 
source of antigen is cleared, most antigen-specific cells die, but a subset of long-lived, resting TM 
cells persists (Kaech et al., 2003). TM cells have a unique metabolism that renders them equipped 
to rapidly respond should infection or tumor growth recur (Pearce et al., 2013). These extensive 
changes in phenotype and function of T cells go hand in hand with a highly dynamic metabolic 
range (Buck et al., 2015; MacIver et al., 2013). As such, these cells represent a distinctive and 
amenable system in which we can study marked changes in cellular metabolism that occur as 
part of normal cellular development, and not as a result of transformation. 
 
Both OXPHOS and aerobic glycolysis generate energy in the form of ATP, but importantly, are 
also critical for other essential processes such as the building of biosynthetic precursors for 
biomass, the production of reactive oxygen species (ROS), and the balance of reducing/oxidizing 
equivalents like NADH/NAD+ which take part in redox reactions that release energy from 
nutrients. Naïve T (TN) cells use OXPHOS for their metabolic needs, but both OXPHOS and 
aerobic glycolysis are augmented upon activation (Chang et al., 2013; Sena et al., 2013). The 
latter is characterized by the preferential conversion of pyruvate to lactate in the cytoplasm rather 
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than its oxidation in the TCA cycle. TM cells predominantly use OXPHOS like TN cells, but have 
enhanced mitochondrial capacity that is marked by their reliance on FAO to fuel OXPHOS (van 
der Windt et al., 2012; van der Windt et al., 2013). Failure to engage specific metabolic 
programs impairs the function and differentiation of T cells (Pearce and Pearce, 2013). 
Establishing the precise reasons why, and how, these and other cells emphasize one particular 
metabolic pathway over another remains a challenging prospect. 
 
Mitochondria are essential hubs of metabolic activity, antiviral responses, and cell death 
(Nunnari and Suomalainen, 2012). These dynamic organelles constantly remodel their structure 
through fission and fusion events mediated by highly conserved nuclear encoded GTPases 
(Ishihara et al., 2013; Youle and van der Bliek, 2012). Mitochondrial fission generates smaller, 
discrete and fragmented mitochondria that can increase ROS production (Yu et al., 2006), 
facilitate mitophagy (Frank et al., 2012), accelerate cell proliferation (Marsboom et al., 2012; 
Taguchi et al., 2007), and mediate apoptosis (Youle and Karbowski, 2005). Dynamin-related 
protein 1 (Drp1) is a cytosolic protein that translocates to the outer mitochondrial membrane 
(OMM) upon phosphorylation to scission mitochondria (Ingerman et al., 2005; Labrousse et al., 
1999; Wakabayashi et al., 2009). Fusion of mitochondria into linear or tubular networks limits 
deleterious mutations in mitochondrial DNA (mtDNA) (Santel et al., 2003), induces 
supercomplexes of the ETC maximizing OXPHOS activity (Cogliati et al., 2013; Mishra et al., 
2014; Zorzano et al., 2010), and enhances endoplasmic reticulum (ER) interactions important for 
calcium flux (de Brito and Scorrano, 2008). In addition, mitochondria elongate as a survival 
mechanism in response to nutrient starvation and cell stress, linking fusion to cellular longevity 
(Friedman and Nunnari, 2014; Gomes et al., 2011; Rambold et al., 2011a). OMM fusion is 
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mediated by mitofusin 1 and 2 (Mfn1, Mfn2) isoforms (Chen et al., 2003), while inner 
membrane fusion is controlled by optic atrophy 1 (Opa1) protein (Cipolat et al., 2004). Complete 
organismal deficiency in any of these proteins is embryonically lethal and mutations in the genes 
that encode them underlie the cause of several human diseases (Archer, 2014; Chan, 2012; Chen 
et al., 2007; Zhang et al., 2011). 
 
Mitochondrial membrane remodeling has been largely demonstrated to be acutely responsive to 
changes in cellular metabolism (Mishra and Chan, 2016; Wai and Langer, 2016), but whether it 
plays a dynamic role in shaping metabolic pathways has been inferred but not extensively 
studied. At the cellular level, deletion of any of the fission and fusion machinery perturbs 
OXPHOS and glycolytic rates at baseline (Liesa and Shirihai, 2013). Tissue-specific deletion of 
Mfn2 in muscles of mice disrupts glucose homeostasis (Sebastian et al., 2012) and Drp1 ablation 
in the liver results in reduced adiposity and elevated whole-body energy expenditure, protecting 
mice from diet-induced obesity (Wang et al., 2015b). A recent study has also suggested a link 
between Drp1 mediated fission and its affect on glycolysis during cell transformation 
(Serasinghe et al., 2015). The central question of whether fission/fusion and associated changes 
in cristae morphology actively control the adoption of distinct metabolic programs and therefore 
regulates T cell responses however, remains unanswered. 
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Unlike TE cells, TM cells maintain a fused mitochondrial network 
 
We reported that TM cells have more mitochondrial mass than TE or TN cells and suggested that 
mitochondria in these T cell subsets possess distinct morphologies (van der Windt et al., 2012; 
van der Windt et al., 2013). These observations prompted us to more closely assess 
mitochondrial structure in T cells. We infected mice with Listeria monocytogenes expressing 
ovalbumin (OVA) (LmOVA) and isolated TE and TM cells for ultrastructure analysis by electron 
microscopy (EM). We found that TE cells had small, distinct mitochondria dispersed in the 
cytoplasm, while TM cells had more densely packed, somewhat tubular, mitochondria (Figure 
6A). In order to more thoroughly investigate these morphological differences, we differentially 
cultured activated OVA-specific T cell receptor (TCR) transgenic OT-I cells in interleukin-2 (IL-
2) and IL-15 to generate IL-2 TE and IL-15 TM cells (Figure 7) (Carrio et al., 2004). These 
culture conditions approximate T cell responses in vivo and allow us to generate large numbers 
of cells amenable to further experimentation in vitro (O'Sullivan et al., 2014). We found that IL-
2 TE and IL-15 TM cells possessed similar mitochondrial ultrastructure as their ex vivo isolated 
counterparts (Figure 6B). Next, we acquired live Z-stacked images of these T cells over time by 
confocal microscopy and found that while at day 1 after activation the mitochondria appeared 
fused, from days 2-6 after activation, IL-2 TE cells exhibited predominantly punctate 
mitochondria (Figure 6C). In contrast, once cells were exposed to IL-15, a cytokine that 
supports TM cell formation (Schluns et al., 2002), the mitochondria formed elongated tubules 
(Figure 6C). Magnified 3D rendered images from these experiments emphasized the marked 
differences in mitochondrial morphology between the IL-2 TE and IL-15 TM cells (Figure 6D). 
Together these data suggest that the mitochondria in TE cells are actively undergoing fission, 
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while in TM cells, these organelles exist in a fused state. To further investigate these changes in 
mitochondrial morphology, we assessed the expression of several critical protein regulators of 
mitochondrial dynamics. We found that by day 6, fusion mediators Mfn2 and Opa1 were lower 
in TE cells compared to TM cells, while fission factor Drp1 was more highly phosphorylated at its 
activating site Ser616 in TE cells (Figure 6E) (Marsboom et al., 2012). These data are consistent 
with our observations that mitochondria in TM cells appear more fused than those in TE cells. 
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Figure 6. Effector and memory T cells possess distinct mitochondrial morphologies.  
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(A) C57BL/6 mice were infected i.p. with 1x107 CFU LmOVA. Effector (TE, CD44hi CD62Llo, 7 
days post infection) and memory T (TM, CD44hi CD62Lhi, 21 days post infection) cells were 
sorted and analyzed by EM as well as (B) IL-2 TE and IL-15 TM cells generated from differential 
culture of OT-I cells activated with OVA peptide and IL-2 using IL-2 or IL-15, scale bar = 0.5 
µm. (C-D) Mitochondrial morphology was analyzed in live OT-I PhAM cells over time before 
and after αCD3/CD28 activation and differential cytokine culture by spinning disk confocal 
microscopy. Mitochondria are green (GFP) and nuclei are blue (Hoechst). (C) Scale bar = 5 µm, 
(D) Scale bar = 1 µm. (E) Immunoblot analysis of cell protein extracts from (C), probed for 
Mfn2, Opa1, Drp1, phosphorylated Drp1 at Ser616 (Drp1pS616), and β-actin. (A-E) Results 
representative of 2 experiments. 
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Figure 7. In vitro differentiation of IL-2 TE and IL-15 TM cells approximate T cell response 
conditions that generate TE and TM cells in vivo. 
 
 
OT-I cells were activated with IL-2 and either OVA peptide or αCD3/CD28 for 3 days and then 
differentially cultured in IL-2 or IL-15 for an additional 3 days to generate IL-2 TE and IL-15 TM 
cells, respectively. 
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Mitochondrial inner membrane fusion protein Opa1 is necessary for TM cell generation 
 
We questioned next whether mitochondrial fusion was important for TM cell generation and 
survival. We crossed Mfn1, Mfn2, and Opa1 floxed mice to OT-I CD4 Cre transgenic mice to 
conditionally delete these proteins in T cells. Peripheral T cell frequencies in these mice were 
grossly normal (data not shown). We differentially cultured these Mfn1-/-, Mfn2-/-, and Opa1-/- 
OT-I T cells in IL-2 and IL-15 and found that only Opa1-/- T cells displayed a selective defect in 
survival when cultured in IL-15 (Figure 8A). Opa1 deficiency did not effect IL-2 TE cell 
survival. We measured the efficiency of gene deletion by mRNA and/or protein analyses (Figure 
9A-C). While Mfn1 and 2 were efficiently deleted, we found some residual expression of Opa1 
particularly in IL-15 TM cells, suggesting that we were selecting for cells that retained expression 
of Opa1 in IL-15 culture conditions, albeit at a diminished level as most of these cells die 
(Figure 8A). We also assessed mitochondrial ultrastructure and, in agreement with published 
results for other cell types (Cogliati et al., 2013; Zhang et al., 2011), mitochondrial cristae were 
significantly altered and disorganized in the absence of Opa1 (Figure 8B). Consistent with their 
survival defect, Opa1-/- IL-15 TM cells exhibited decreased OXPHOS activity, as measured by O2 
consumption rate (OCR, an indicator of OXPHOS) to extracellular acidification rate (ECAR, an 
indicator of aerobic glycolysis) ratio, and spare respiratory capacity (SRC), compared to normal 
cells (Figure 8C). SRC is the extra mitochondrial capacity available in a cell to produce energy 
under conditions of increased work or stress and is thought to be important for long-term cellular 
survival and function (measured as OXPHOS activity above basal after uncoupling with FCCP) 
(Choi et al., 2009; Ferrick et al., 2008; Nicholls, 2009; Nicholls et al., 2010; van der Windt et al., 
2012; Yadava and Nicholls, 2007). To determine whether Opa1 function is required for TM cell 
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development in vivo, we adoptively transferred naïve Opa1-/- OT-I T cells into congenic 
recipients, infected these mice with LmOVA, and subsequently assessed TM cell formation in the 
weeks after infection. Control and Opa1-/- OT-I T cells mounted normal TE cell responses (day 7) 
to infection, while Opa1-/- OT-I TM cell formation (days 14-21) was drastically impaired (Figure 
8D). Consistent with diminished TM cell development, a significantly higher proportion of short-
lived effector cells to memory precursor effector cells were present within the Opa1-/- OT-I 
donor cell population 7 days after infection (Figure 9D) (Kaech et al., 2003). In addition, at day 
10 post-infection, a time point at which TE cells contract, while TM cells emerge, Opa1-/- T cells 
isolated ex vivo had decreased SRC compared to control cells (Figure 9E), correlating with their 
decreased survival. To assess whether Opa1-/- TM cells existed in too low an abundance to be 
discerned by flow cytometry, we challenged these mice with a second infection. We observed no 
recall response (day 3 and 6 p.c.) from Opa1-/- T cells when assessing frequency (Figure 8E) or 
absolute numbers (Figure 8F), while there was considerable expansion of control donor cells. 
These data illustrate that Opa1 function is required for TM cell, but not TE cell generation. 
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Figure 8. Memory T cell development and survival, unlike effectors, requires 
mitochondrial fusion.  
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(A) Relative in vitro survival ratios of Mfn1, Mfn2, or Opa1 deficient (CD4 Cre+, -/-) to wild-
type control (CD4 Cre-, +/+) OT-I IL-2 TE and IL-15 TM cells (*p=0.0465). Data normalized 
from 2-3 independent experiments shown as mean ± SEM. (B) Mitochondrial morphology of 
OT-I Opa1 wild-type and Opa1 knockout IL-2 TE and IL-15 TM cells analyzed by EM (scale bar 
= 0.5 µm, one experiment represented) and (C) Seahorse EFA. (Left) bar graph represents ratios 
of O2 consumption rates (OCR, an indicator of OXPHOS) to extracellular acidification rates 
(ECAR, an indicator of aerobic glycolysis) at baseline and (right) spare respiratory capacity 
(SRC) (% max OCR after FCCP injection of baseline OCR) of indicated cells (*p<0.03, 
**p=0.0079). Data from 3 experiments shown as mean ± SEM. (D-F) 104 OT-I Opa1+/+ or Opa1-
/- T cells were transferred i.v. into C57BL/6 CD90.1 mice infected i.v. with 1x107 CFU LmOVA. 
Blood was analyzed by flow cytometry at indicated time points post infection. After 21 days, 
mice were challenged i.v. with 5x107 CFU LmOVA and blood analyzed post challenge (p.c.). 
(D) % Donor Kb/OVA+ and CD90.2+ live cells shown in representative flow plots and (E) line 
graph with mean ± SEM. (*p=0.0238, **p<0.005). (F) Number of donor Kb/OVA+ cells isolated 
from spleens of infected mice shown as mean ± SEM (*p=0.0126). (D-F) Results representative 
of 2 experiments (n=9-11 per group). 
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Figure 9. Assessment of genetic deletion of mitochondrial fusion proteins in IL-2 TE and 
IL-15 TM cells and of donor TE cells generated from infection. 
  
 95 
(A-C) IL-2 TE and IL-15 TM cells were cultured from (A) OT-I Mfn1 floxed, (B) OT-I Mfn2 
floxed, (C) OT-I Opa1 floxed mice crossed to CD4 Cre transgenic mice to generate T cells 
conditionally deleted for proteins that mediate mitochondrial fusion (+/+ are CD4 Cre- and -/- are 
CD4 Cre+). Efficiency of deletion by cre recombinase analyzed by (A) qPCR and (B-C) 
immunoblot. (D) Flow cytometry analysis of short-lived effector cells  (SLEC, KLRG1hi 
CD127lo) and memory precursor effector cells (MPEC, KLRG1lo CD127hi) generated at day 7 
post infection from OT-I Opa1+/+ and OT-I Opa1-/- cells transferred into congenic recipients 
infected with LmOVA. Representative flow dot plots (left) and scatter dot plots (right) with 
mean ± SEM bars. Each dot represents individual mice (n=8-9 per genotype), ***p<0.0001. (E) 
OCR analysis of day 10 post-infection OT-I Opa1+/+ and Opa1-/- donor cells at baseline and after 
oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A) injections. Data is 
representative of 2 experiments shown as mean ± SEM. 
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Mitochondrial fusion imposes a TM cell phenotype, even in the presence of activating 
signals 
Genetic loss of function of Opa1 revealed that this protein is critical for TM cell formation. Given 
the fused phenotype of mitochondria in these cells, we hypothesized that Opa1-mediated 
mitochondrial fusion supports the metabolism needed for TM cell development. We used a gain 
of function approach to enhance mitochondrial fusion. Culturing T cells with the ‘fusion 
promoter’ M1 (Wang et al., 2012), and the ‘fission inhibitor’ Mdivi-1 (Cassidy-Stone et al., 
2008) (Figure 10A), induced mitochondrial fusion in IL-2 TE cells, rendering them 
morphologically similar to IL-15 TM cells (Figure 10B). Treatment with these drugs enhanced 
other TM cell properties in activated IL-2 TE cells, including increased mitochondrial mass 
(Figure 10C), OXPHOS and SRC (Figure 10D), CD62L expression (Figure 10E) and robust 
metabolic activity, as indicated by bioenergetic profiling of the cells in response to secondary 
stimulation with PMA/ionomycin, followed by addition of oligomycin (ATP synthase inhibitor), 
FCCP, and rotenone plus antimycin A (ETC complex I and III inhibitors), all drugs that stress 
the mitochondria (Figures 10F and 11A) (Nicholls et al., 2010). However, we did not observe 
increased mtDNA in these cells (Figure 11B). We found that ECAR and the OCR/ECAR ratio 
increased after drug treatment (Figure 11C), indicating elevated metabolic activity overall, with 
a predominant increase in OXPHOS over glycolysis. While we observed these changes in 
mitochondrial activity, we did not measure any significant differences in mitochondrial 
membrane potential or ROS production after drug treatment (Figure 11D). The expression of 
other activation markers were also not substantially affected, although a small decrease in 
KLRG1 and increase in CD25 was measured (Figure 11E). Additionally, we performed a 
genetic gain of function experiment and transduced activated IL-2 TE cells with retrovirus 
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expressing Mfn1, Mfn2, or Opa1. Similar to enforcement of fusion pharmacologically, we found 
that cells transduced with Opa1 had more mitochondria (Figure 10G) and OXPHOS (Figure 
10H), than empty vector control or Mfn-transduced T cells, as well as increased overall 
metabolic activity, with a predominant increase in OXPHOS over glycolysis (Figure 11F).  TM 
cell associated markers such as CCR7 and CD127 were increased on transduced cells, as well as 
TE cell proteins, such as PD-1 (Figure 11G). We confirmed by mRNA expression that each 
target gene had increased expression after transduction over the control (Figure 11G). Together 
our results show that mitochondrial fusion confers a TM cell phenotype on activated TE cells even 
in culture conditions that program TE cell differentiation. 
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Figure 10. Enhancing mitochondrial fusion promotes the generation of memory-like T 
cells. 
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(A-F, I-L) OVA peptide and IL-2 activated OT-I cells were differentiated into IL-2 TE or IL-15 
TM cells for 3 days in the presence of DMSO control or fusion promoter M1 and fission inhibitor 
Mdivi-1 (M1+Mdivi-1) as shown in (A) pictorially. (B) Representative spinning disk confocal 
images from 3 experiments of live cells generated from OT-I PhAM mice. Mitochondria are 
green (GFP) and nuclei are blue (Hoechst), scale bar = 5 µm. (C) Cells stained with MitoTracker 
Green and analyzed by flow cytometry. Relative MFI (left) from 6 experiments shown as mean ± 
SEM (*p=0.0394, **p=0.0019) with representative histograms (right). (D) Baseline OCR and 
SRC of indicated cells from 3-4 experiments shown as mean ± SEM (*p=0.0485, ***p<0.0001). 
(E) CD62L expression analyzed by flow cytometry of indicated cells. Relative MFI (left) from 7 
experiments shown as mean ± SEM (*p=0.0325, **p=0.0019, ***p<0.0001) with representative 
histograms (right). (F) OCR of indicated cells at baseline and in response to PMA and ionomycin 
stimulation (PMA+iono), oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A). 
Data represents 2 experiments shown as mean ± SEM. (G-H) OT-I cells were transduced with 
either empty (Control), Mfn1, Mfn2, or Opa1 expression vectors, sorted, and cultured to generate 
IL-2 TE cells. (G) Histograms representative of 4 experiments of cells stained for MitoTracker 
Deep Red and (H) OCR data at baseline of transduced cells from 2 experiments. (I-L) 1-2x106 
IL-2 TE cells cultured with DMSO (gray diamonds) or M1+Mdivi-1 (blue squares) were 
transferred into congenic C57BL/6 recipient mice. Cell counts of donor cells recovered 2 days 
later from the (I) spleen (***p=0.005) and (J) peripheral lymph nodes (pLNs, ***p=0.0006). (K) 
Blood from recipient mice analyzed for % donor Kb/OVA+ cells post transfer and challenge with 
1x107 CFU LmOVA by flow cytometry (*p=0.0150, n=5 per group). (L) Donor Kb/OVA+ cells 
recovered from recipient spleens 6 days post challenge (*p=0.0383). (I-L) Data represents 2 
experiments shown as mean ± SEM.  
 100 
Figure 11. Assessment of T cell phenotype and metabolism following pharmacological or 
genetic enhancement of mitochondrial fusion. 
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(A-E) IL-2 TE and IL-15 TM cells generated from OT-I mice were treated with DMSO control or 
M1+Mdivi-1. (A) ECAR of indicated cells at baseline and after PMA and ionomycin 
(PMA+iono) stimulation, oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A). (B) 
qPCR analysis of relative mitochondrial DNA (mtDNA) to nuclear DNA (nDNA) ratios of 
indicated cells. (C) ECAR (left) and OCR/ECAR ratios (right) of indicated cells under basal 
conditions. (D) Histograms of membrane potential (CMxROS, TMRM) and mitochondrial ROS 
(MitoSOX) using indicated fluorescent dyes and (E) KLRG1, CD127, CCR7, and CD25 surface 
marker expression of indicated cells analyzed by flow cytometry. (F-H) OT-I IL-2 TE cells were 
activated and transduced with empty vector (Control), Mfn1, Mfn2, or Opa1 expressing 
retrovirus. (F) ECAR, OCR/ECAR, and SRC analyzed by Seahorse EFA, (G) KLRG1, CD127, 
CCR7, CD25 and PD-1 surface marker expression assessed by flow cytometry, and (H) gene 
expression analysis by qPCR.  (A-G) Data are shown as mean ± SEM and are representative or 
(B-C, F) combined from 2-3 experiments, not significant (ns), **p<0.001, ***p<0.0001. 
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T cell mitochondrial fusion improves adoptive cellular immunotherapy against tumors 
 
A major consideration when designing adoptive cellular immunotherapy is to improve T cell 
fitness during ex vivo culture, so that when T cells are re-introduced into a patient they are able 
to function efficiently and persist for long periods of time (Maus et al., 2014; O'Sullivan and 
Pearce, 2015; Restifo et al., 2012). Our data showed that fusion-promoting drugs created 
metabolically fit T cells.  We hypothesized that enforced fusion would also enhance the 
longevity of IL-2 TE cells in vivo. To test this, we adoptively transferred control and M1+Mdivi-
1 treated OT-I T cells into congenic mice and tracked donor cell survival. We found significantly 
more drug treated T cells in the spleen (Figure 10I) and lymph nodes (Figure 10J) 2 days after 
transfer.  To determine if the persistence of these cells would be maintained better long term than 
control cells, we infected mice with LmOVA more than 3 weeks later and measured T cell 
responses against the bacteria. We found that drug-treated cells selectively expanded in response 
to infection (Figure 10K) and could be recovered in significantly greater numbers in the spleen 6 
days post-challenge (Figure 10L). 
 
Next, we assessed whether these drugs could be used to promote T cell function in a model of 
adoptive cell immunotherapy. We injected EL4-OVA tumor cells into mice. Then either 5 or 12 
days later we adoptively transferred IL-2 TE cells that had been previously treated with DMSO or 
M1+Mdivi-1. In both settings, mice that had received ‘fusion-promoted’ T cells were able to 
control tumor growth significantly better than mice that had received control treated cells 
(Figures 12A and B).  The cytolytic ability (Figure 13A) and proliferation (Figure 13B) of the 
modified IL-2 TE cells were similar to control cells, however, fusion enforced IL-2 TE cells 
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expressed significantly higher levels of IFN-γ and TNF-α when restimulated with PMA and 
ionomycin in vitro (Figure 13C). We also exposed activated human T cells to M1+Mdivi-1 
treatment in vitro and found that activated human IL-2 TE cells had visibly more fused 
mitochondria (Figure 12C), and exhibit the bioenergetic profile (Figure 12D), and surface 
marker expression (Figure 12E) characteristic of TM cells, compared to control treated cells. 
Parameters such as mitochondrial mass (Figure 12E) and other surface markers (Figure 13D) 
were not significantly altered. These data suggest that promoting fusion in T cells may be a 
translatable treatment for enhancing human therapy. 
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Figure 12. Mitochondrial fusion improves adoptive cellular immunotherapy against 
tumors. 
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(A-B) C57BL/6 mice were inoculated s.c. with 1x106 EL4-OVA cells. (A) After 5 or (B) 12 
days, 1x106 or 5x106 OT-I IL-2 TE cells cultured with DMSO or M1+Mdivi-1 were transferred 
i.v. into recipient mice and tumor growth assessed. Data represents 2 experiments shown as 
mean ± SEM (n=5 per group, *p<0.05, **p<0.005). (C-E) Human CD8+ PBMCs were activated 
with αCD3/CD28 + IL-2 to generate IL-2 TE cells. (C) Confocal images of indicated treated cells 
where mitochondria are green (MitoTracker) and nuclei are blue (Hoechst). Representative 
images from 2 of 4 biological donors, scale bar = 5 µm. (D) OCR/ECAR ratios and SRC of 
indicated cells from 2 separate donors shown as mean ± SEM (*p=0.0303, **p<0.005, 
***p<0.0001). (E) MitoTracker Green staining and CD62L, CD45RO, and CCR7 expression 
analyzed by flow cytometry shown with representative histograms from 4-6 biological replicates. 
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Figure 13. Examination of mouse and human IL-2 TE cells after enforcing mitochondrial 
fusion with drugs. 
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(A-C) Flow cytometry analyses of IL-2 TE cells previously cultured with DMSO or M1+Mdivi-1 
combined from 3 biological replicates. Cells were not subjected to further treatment with DMSO 
or M1+Mdivi-1 during experiment assays. (A) Cytolysis of EL4-OVA target cells at indicated 
concentrations. (B) Proliferation after restimulation with αCD3/CD28. (C) Intracellular cytokine 
staining after 4 hours stimulation with PMA and ionomycin. Relative MFI (left) with mean ± 
SEM and representative contour plots (right) with percentage of cytokine positive cells indicated 
in gated cells and MFI in bold, *p<0.05. Gates based on unstimulated cells (not shown). (D) 
Human CD8+ PBMCs were activated with αCD3/CD28 + IL-2 to generate IL-2 TE cells and 
subjected to DMSO or M1+Mdivi-1 treatment. KLRG1, CD127, CD45RA, and CD25 surface 
marker expression analyzed by flow cytometry shown with representative histograms from 4-6 
biological replicates.  
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Mitochondrial fusion promotes TM cell metabolism, but Opa1 is not required for FAO 
 
Our data showed that Opa1 was a necessary regulator of TM cell development, but the question 
of precisely how Opa1 acted to support TM cells remained.  We hypothesized that mitochondrial 
fusion, via Opa1 function, was needed for FAO, as the engagement of this pathway is a 
requirement for TM cell development and survival (Pearce et al., 2009; van der Windt et al., 
2012; van der Windt et al., 2013). This hypothesis was not only based on our observations that 
these two processes seemed to be linked in TM cells, but also on a recent study showing that 
mitochondrial fusion is important for efficient FAO via lipid droplet trafficking under starvation 
conditions (Rambold et al., 2015). We treated IL-2 TE and IL-15 TM cells with M1+Mdivi-1 or 
vehicle and then measured OCR in response to etomoxir, a specific inhibitor of mitochondrial 
long chain FAO (Deberardinis et al., 2006), and mitochondrial inhibitors. We found that the 
increased OCR and SRC evident in these cells after M1+Mdivi-1 treatment was due to 
augmented FAO (Figures 14A and 15A). IL-2 TE cells transduced with Opa1 also exhibited 
enhanced OCR that decreased in the presence of etomoxir compared to control cells (Figure 
14B). Bone marrow derived macrophages (BM-Macs) cultured with M1+Mdivi-1 also increased 
OCR and SRC to levels similar as M2 polarized macrophages, which engage FAO much like TM 
cells do (Figure 15B) (Huang et al., 2014). Importantly, M1+Mdivi-1 treatment did not increase 
OCR (Figure 14C) and did not affect ECAR (Figure 15C) in Opa1-/- IL-2 TE cells compared to 
controls, suggesting a requirement for Opa1 in augmenting OCR and FAO. However, in contrast 
to what we expected, when we assessed bioenergetics of Opa1+/+ and Opa1-/- IL-2 TE cells 
(Figure 14D) and ex vivo isolated TE cells (Figure 14E), we found that both cell types are 
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equally responsive to etomoxir. Our results show that while Opa1 could promote FAO in T cells, 
it was not compulsory for engagement of this metabolic pathway. 
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Figure 14. Fusion promotes memory T cell metabolism, but Opa1 is not required for FAO. 
 
 
(A-E) OCR measured at baseline and in response to media, etomoxir (Eto) and other drugs as 
indicated of (A) IL-2 TE cells cultured in DMSO or M1+Mdivi-1, (B) control or Opa1 
transduced IL-2 TE cells, (C) Opa1+/+ and Opa1-/- IL-2 TE cells cultured in DMSO or M1+Mdivi-
1 (D) or without drugs, and (E) ex vivo donor OT-I Opa1+/+ and Opa1-/- day 7 TE cells derived 
from LmOVA infection. (A-E) Data representative of 2 independent experiments shown as mean 
± SEM (***p<0.0001).  
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Figure 15. Bioenergetics analysis after promoting mitochondrial fusion in T cells and 
macrophages. 
 
(A) OCR of IL-15 TM DMSO or M1+Mdivi-1 treated cells measured at baseline and in response 
to media, etomoxir (Eto), oligomycin (Oligo), FCCP, and rotenone plus antimycin A (R+A). (B) 
Bone marrow derived macrophages were cultured overnight with IL-4 (M2) or without (M0) and 
either DMSO or M1+Mdivi-1 overnight. OCR analyzed at baseline and after injection of 
mitochondrial inhibitors as indicated. (C) Baseline ECAR relative to DMSO controls of IL-2 TE 
Opa1+/+ and Opa1-/- cells cultured in DMSO or M1+Mdivi-1. (A-C) Data are shown as mean ± 
SEM and are representative of 2-3 experiments. 
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Mitochondrial cristae remodeling signals metabolic adaptations in TM and TE cells 
 
Although both Opa1+/+ and Opa1-/- IL-2 TE cells could equally engage FAO (Figure 14D), we 
observed that ECAR was significantly augmented in the Opa1-/- cells both in vitro and ex vivo 
(Figure 16A). Furthermore, unlike control cells, we observed no additional drop of OCR in 
Opa1-/- IL-2 TE cells after the addition of oligomycin (Figure 16B), suggesting that in the 
absence of Opa1, only FAO supports OXPHOS, and that oxidation of other substrates, such as 
glucose-derived pyruvate, are not utilized for mitochondrial ATP production in this setting. We 
cultured Opa1+/+ and Opa1-/- IL-2 TE cells with 13C-labeled glucose and traced 13C into TCA 
cycle metabolites. We found that while the percent of 13C-labeled pyruvate was higher in the 
Opa1-/- T cells, the frequency of 13C-labeled TCA cycle intermediates was significantly reduced 
in the Opa1-/- T cells compared to controls (Figures 16C and 17A), a result that is supported by 
their higher ECAR (Figure 16A). These data suggested that without mitochondrial fusion, 
pyruvate is preferentially secreted as lactate, rather than oxidized in the mitochondria. Therefore, 
we questioned whether FAO was a ‘default’ pathway for mitochondria in a resting, or fused state 
(i.e. Opa1 sufficiency), and that the induction of aerobic glycolysis is a major downstream effect 
of fission (i.e. Opa1 deficiency). If this were the case, then a balance between fission and fusion, 
modulated by proteins such as Opa1, could act as a primary signal to dictate the metabolic 
phenotype of T cells. In support of this idea, T cells from polyclonal T cell-conditional deleted 
Opa1 animals had higher ECAR and an increased proportion of CD8 T cells with an activated 
effector phenotype in the basal state based on surface marker expression (Figure 17B). 
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Opa1 is critical for inner mitochondrial membrane fusion, but also for other processes like cristae 
remodeling (Cogliati et al., 2013; Frezza et al., 2006; Varanita et al., 2015). We observed major 
changes in cristae morphology in the Opa1-/- T cells (Figure 8B). Given the importance of Opa1 
function in TM cell development (Figure 8), we further assessed cristae morphology in TE and 
TM cells isolated ex vivo after LmOVA infection (Figure 16D), as well as in IL-2 TE and IL-15 
TM cells (Figure 16E), and found that TE cells had many cristae with what appeared to be 
slightly wider, or more loosely organized intermembrane space, than TM cells.  It has been found 
that Opa1 overexpression induces cristae tightening and close association of ETC complexes in 
the inner mitochondrial membrane (Civiletto et al., 2015; Cogliati et al., 2013). Therefore, we 
surmised that in the absence of Opa1, cristae disorganization leads to dissociation of ETC 
complexes, and subsequently less efficient ETC activity, in T cells (Figure 8C). We assessed 
OCR after oligomycin in relation to OCR after rotenone plus antimycin A treatment (i.e. proton 
leak), which indicates the coupling efficiency of OXPHOS with mitochondrial ATP production. 
Consistent with decreased OXPHOS efficiency, we observed increased proton leak in Opa1-/- T 
cells compared to control cells (Figure 16F). This was also true for ex vivo isolated TE cells 
when compared to TM cells (Figure 16G), as well as IL-2 TE and IL-15 TM cells (Figure 16H). 
Together these data suggest that there are cristae differences between TE and TM cells which may 
contribute to their distinct metabolic phenotypes. 
 
We reasoned that fusion renders tightly configured cristae, which results in closely associated 
ETC complexes and efficient OXPHOS (Patten et al., 2014), producing conditions that favor the 
entrance of pyruvate into the TCA cycle. In this situation, NADH generated from the TCA cycle 
is able to easily donate electrons to complex I, which are passed efficiently along the ETC. Our 
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data suggested that this predominantly occurs in TM cells. However, if electron transport across 
the ETC becomes less efficient, which could be caused by physical separation of the individual 
complexes due to cristae remodeling via mitochondrial fission, then electrons could linger in the 
complexes and imbalance redox reactions. NADH levels would build, slowing forward 
momentum of the TCA cycle. To restore redox balance, cells could augment glycolysis and 
shunt pyruvate as excreted lactate (i.e. aerobic glycolysis), which would regenerate NAD+ from 
NADH in the cytosol. We speculated that this is what occurs in TE cells. Correlating with this 
idea, we previously reported that TE and TM cells have different ratios of NAD+/NADH (i.e. 
redox balance), with TM cells maintaining higher NAD+/NADH than TE cells. We also showed 
that NADH levels dramatically rise in TM cells compared to TE cells when exposed to 
rotenone/antimycin A, indicating that TM cells continually consume more NADH for the purpose 
of donating electrons to the ETC (van der Windt et al., 2012). Together our data suggested that 
fission and fusion events regulate cristae remodeling, which could alter ETC efficiency and 
redox balance, ultimately controlling metabolic adaptations in T cells. 
 
To more thoroughly examine this idea, we assessed cristae morphology in TE and TM cells by 
EM following TCR stimulation. We hypothesized that if cristae remodeling acts to induce 
aerobic glycolysis, changes in cristae structure could be visualized following T cell activation. 
TM cells rapidly augment aerobic glycolysis when restimulated (van der Windt et al., 2013). We 
activated IL-15 TM cells with αCD3/CD28-conjugated beads (Figure 16I), or with PMA and 
ionomycin (Figure 17C), in the presence or absence of Mdivi-1, to modulate activity of the 
mitochondrial fission protein Drp1 (Cassidy-Stone et al., 2008). We observed dramatic changes 
to cristae morphology by EM, with the intermembrane space widening over time in control cells 
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in comparison to drug treated cells. These data are consistent with the hypothesis that fission-
induced mitochondrial cristae remodeling supports metabolic reprogramming in T cells. 
 
TM cells maintain tight cristae with closely associated ETC complexes 
Our data suggested that unlike TE cells, TM cells have tight cristae with close association of the 
ETC complexes. To investigate this biochemically, we treated native lysates of IL-2 TE and IL-
15 TM cells with increasing concentrations of digitonin to disrupt all cellular membranes 
(including mitochondrial). The crude membrane-bound fraction was separated from solubilized 
proteins by centrifugation. Both pellet and soluble supernatant fractions were loaded on a 
denaturing reducing gel and then probed for various mitochondrial proteins by western blot. We 
found that mitochondria in IL-2 TE cells were susceptible to digitonin disruption, indicated by 
the fact that ETC complex proteins became less detectable in the pellet, and amplified in the 
soluble fraction, in 0.5% detergent (Figures 16J and 17D). This was in contrast to IL-15 TM 
cells, where ETC proteins did not solubilize to the same extent as those in IL-2 TE cells into the 
supernatant, even when 2% digitonin was used. To investigate whether this phenomenon was 
unique to the mitochondrial compartment, we also probed for the ER integral protein calnexin 
and found that it solubilized similarly in 0.5% digitonin in both cell types. Overall these data 
suggest that there is more exposed mitochondrial membrane between proteins in IL-2 TE cells 
than in IL-15 TM cells, and correlate with the idea that TM cells have tight cristae which would 
yield efficient ETC activity, while TE cells have looser cristae with less efficient ETC activity, 
ultimately supporting their distinct metabolic phenotypes. 
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Mitochondrial fission in activated immune cells facilitates aerobic glycolysis  
Our data suggested that cristae remodeling, through fission and fusion events, was a mechanism 
to regulate efficient OXPHOS and FAO in TM cells, as well as the induction of aerobic 
glycolysis in TE cells. To more directly test this idea, we assessed ECAR of IL-15 TM cells that 
were stimulated with αCD3/28-conjugated beads in the presence or absence of Mdivi-1. We 
found that when mitochondrial fission protein Drp1 was inhibited with Mdivi-1, T cell activation 
did not robustly increase aerobic glycolysis when compared control cells (Figure 16K), which 
correlated with our EM data (Figure 16I). Since fission can be associated with cell division 
(Marsboom et al., 2012; Taguchi et al., 2007), we wanted to test our idea in a non-proliferating 
cell type that substantially augments aerobic glycolysis upon stimulation (Everts et al., 2014; 
Everts et al., 2012; Krawczyk et al., 2010). We stimulated bone marrow derived dendritic cells 
(BM-DCs) and macrophages (BM-Macs) with lipolysaccharide (LPS) with or without interferon 
(IFN)-γ in the presence or absence of Mdivi-1 and measured ECAR. Aerobic glycolysis was 
curtailed in both BM-DCs and BM-Macs following stimulation when Drp1 was inhibited 
(Figure 16L). The blunted ECAR in the Mdivi-1 treated cells correlated with significantly 
decreased nitric oxide synthase 2 (Nos2) protein expression in the BM-Macs (Figure 16M), 
indicating that their activation was also repressed. These data indicate that cristae remodeling 
and/or fission acts as a signal to drive the induction of aerobic glycolysis, and subsequent cellular 
activation via Drp1. 
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Figure 16. Mitochondrial cristae remodeling signals metabolic pathway engagement. 
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(A) Basal ECAR of OT-I Opa1+/+ and Opa1-/- IL-2 TE cells (left) and day 7 TE cells isolated ex 
vivo after adoptive transfer from LmOVA infection (right). Data combined from 2-3 experiments 
(*p=0.0412, ***p<0.0001). (B) OCR at baseline and after indicated drugs, representative of 2 
experiments shown as mean ± SEM, and (C) D-Glucose-13C1,2 trace analysis of OT-I Opa1+/+ 
and Opa1-/- IL-2 TE cells. Each lane represents separate mice with a technical replicate. (D) EM 
analysis of mitochondrial cristae from TE and TM cells isolated after LmOVA infection and (E) 
in vitro cultured IL-2 TE and TM cells. Data representative of 2 experiments, scale bar = 0.25 µm. 
Relative proton leak (ΔOCR after oligomycin and subsequent injection of rotenone plus 
antimycin A) of (F) Opa1+/+ and Opa1-/- IL-2 TE, (G) infection elicited TE and TM, and (H) IL-2 
TE and IL-15 TM cells. (F-H) Data combined from 2-4 experiments shown as mean ± SEM 
(p**<0.005, ***p<0.0001). (I) EM analysis of IL-15 TM cell-mitochondrial cristae before and 
after αCD3/CD28-conjugated bead stimulation over hours, scale bar = 0.2 µm and represents one 
experiment. (J) Immunoblot analysis of ER protein Calnexin and ETC complexes (CI-NDUFB8, 
CII-SDHB, CIII-UQCRC2, CIV-MTC01, CV-ATP5A). Equivalent numbers of IL-2 TE and IL-
15 TM cells were lysed in native lysis buffer followed by digitonin solubilization of intracellular 
membranes. Pellet (P) and solubilized supernatant (S) fractions were resolved on a denaturing 
gel. Data representative of 2 experiments. (K) IL-15 TM cell, (L) bone marrow-derived dendritic 
cell (BM-DCs) and macrophage (BM-Macs) % ECAR measured at baseline and after media, 
αCD3/CD28-conjugated bead, LPS, or LPS+IFN-γ injection as indicated. Data are baselined 
prior to or right after injection with stimuli. (M) BM-Macs stained for intracellular Nos2 protein 
by flow cytometry with MFI values (left) and representative histogram (right). (K-M) Data 
shown as mean ± SEM and represent 2-3 experiments (***p<0.0001). 
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Figure 17. T cell activation induces cristae remodeling that regulates metabolism. 
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(A) Activated Opa1+/+ and Opa1-/- IL-2 TE cells were cultured overnight with D-Glucose-13C1,2 
and traced for incorporation by mass spectrometry. Heat map representation of % labeled 
carbons in listed metabolites. (B) Spleens from either polyclonal wild-type  (+/+) or Opa1 
deficient T cell animals (-/- Opa1 T) were isolated and surface marker expression assessed 
(CD44, CD62L on CD3+ CD8+ gates) by flow cytometry (top) or were further purified for CD8 
T cells to assess OCR and ECAR at baseline (below) by Seahorse EFA. Data presented with 
mean ± SEM from n=6 per genotype, ***p<0.0001. (C) EM images of IL-15 TM cell 
mitochondria over time before and after PMA and ionomycin stimulation from one experiment. 
Scale bar = 0.5 µm. (D) Immunoblot analysis of ETC complexes (CI-NDUFB8, CII-SDHB, 
CIII-UQCRC2, CIV-MTC01, CV-ATP5A) and OMM protein Tom20. Equivalent numbers of 
IL-2 TE and IL-15 TM cells lysed in native lysis buffer followed by digitonin solubilization of 
intracellular membranes. Pellet (P) and solubilized supernatant (S) fractions were resolved on a 
denaturing gel. Second experiment represented from Figure 16J. 
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Discussion 
 
Although TM cells rely on FAO for development and survival, precisely why TM cells utilize 
FAO and the signals that drive the induction of aerobic glycolysis in TE cells remain unclear. Our 
data suggest that manipulating the structure of a single organelle can have profound 
consequences that impact metabolic pathway engagement and ultimately, the differentiation of a 
cell. We found that Opa1 regulated tight cristae organization in TM cells, which facilitated 
efficient ETC activity and a favorable redox balance that allowed continued entrance of pyruvate 
into mitochondria. We originally hypothesized that Opa1 would be an obligate requirement for 
FAO. However, we found that Opa-1-/- IL-2 TE cells and ex vivo TE cells generated during 
infection utilized FAO to the same level as cells expressing Opa1. While this was true for TE 
cells, this may not be the case for TM cells, whose survival is severely impaired in vitro and in 
vivo when deficient in Opa1. It is possible that Opa1-/- T cells are unable to form TM cells 
because they cannot efficiently engage FAO under the metabolic constraints imposed during TM 
cell development. Previous studies point to the existence of a ‘futile’ cycle of fatty acid synthesis 
(FAS) and FAO within TM cells (Cui et al., 2015; O'Sullivan et al., 2014) whereby carbon 
derived from glucose oxidation is used to build fat that is subsequently burned by mitochondria 
for fuel. TM cells have a lower overall metabolic rate than TE cells, and tightly configured cristae 
might be important to ensure that any pyruvate generated will efficiently feed into the TCA cycle 
not only for reducing equivalents, but also for deriving citrate for FAS. Without tight cristae and 
efficient ETC activity, electrons may loiter in the complexes, causing more ROS, which could be 
damaging (Chouchani et al., 2014), but also provide signals that drive cell activation (Sena et al., 
2013).  
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We did not observe a defect in TM cell survival in Mfn1 and Mfn2 deficient T cells, but this does 
not exclude the possibility that OMM fusion or additional activities ascribed to each of these 
proteins are not important. Mfn1 and Mfn2 form both homotypic and heterotypic interactions, 
suggesting that in the absence of one protein, the other can compensate (Chen et al., 2003). Our 
preliminary data assessing Mfn1/2 expression in Mfn1-/- and Mfn2-/- T cells indicate that this 
might be occurring (data not shown). However, our results clearly show that unlike Opa1-/- T 
cells, in vitro cultured Mfn1-/- or Mfn2-/- T cells do not have a survival defect when differentiated 
in IL-15 (Figure 8A), even though, like Opa1-/- T cells, they are more glycolytic and OXPHOS-
impaired compared to controls (data not shown). Further investigation using Mfn1/2 double 
knockouts is underway in our laboratory to examine whether a lack of both proteins, and 
presumably total OMM fusion, impairs TM cell development in similar fashion as deficiency in 
inner membrane fusion. Our imaging data showed that TM cells maintained extended fused 
mitochondrial networks, suggesting that OMM fusion also has a compulsory role in TM cell 
development. However, unlike Opa1, retroviral expression of Mfn1 and Mfn2 did not confer a 
TM cell phenotype in TE cells. This could be due to the fact that an increase in OMM fusion, 
without a concomitant increase in inner membrane fusion, would still yield an overall loose 
cristae morphology and redox state that by default, results in sustained excretion of lactate. 
 
The question of what signals drive T cell structural remodeling of mitochondria in the first place 
still remains. In the case of TM cell development, initial withdrawal of activating signals and 
growth factors may induce fusion, consistent with previous reports that starvation induces 
mitochondrial hyperfusion (Rambold et al., 2015; Rambold et al., 2011b), an effect we also 
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observe in TE cells after IL-2 withdrawal (data not shown). However, pro-survival signals from 
cytokines such as IL-15 or IL-7 are needed to sustain TM cell viability and metabolically remodel 
these cells for FAS and FAO via increased CPT1a (van der Windt et al., 2012) and aquaporin 9 
expression (Cui et al., 2015). Factors such as these may enforce the fused state and would be 
consistent with our observations that activated T cells subsequently cultured in IL-15 become 
more fused over time (Figure 6D). Another possibility is that Opa1 is activated via sirtuin 3 
(SIRT3) under metabolically stressful conditions (Samant et al., 2014). Sirtuins are post-
translational modifiers that are activated by NAD+, directly tying their activity to the metabolic 
state of the cell (Houtkooper et al., 2012; Wang and Green, 2012). Our previous work 
demonstrated that the available NAD+ pool is higher in TM cells (van der Windt et al., 2012), 
which could correlate with this scenario. 
 
In TE cells we see an immediate activation of Drp1, prior to seeing a fissed phenotype, and 
inhibition of Drp1 prevents ECAR induction after activation. TCR signals induce Ca2+ flux that 
activates the phosphatase activity of calcineurin (Smith-Garvin et al., 2009), which in turn 
dephosphorylates Drp1 at Ser637, leading to its activation (Cereghetti et al., 2008). Initial Drp1 
activation could facilitate some level of fission and cristae remodeling, tipping off aerobic 
glycolysis via the initial shunting of pyruvate to lactate. Our data (Figure 6E) showed that Drp1 
is phosphorylated at its activating site Ser616 at day 1 after activation, which preceded 
recognizable mitochondrial fragmentation (Figure 6C). Our preliminary data did not show overt 
mitochondrial fragmentation in the initial hours after TLR stimulation of DC or macrophages 
(data not shown), but this does not exclude the possibility that Drp1 is actively mediating more 
subtle changes to mitochondrial structure that are not discernable by confocal microscopy. For 
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example, Drp1 also has been found to affect cristae structure by altering the fluidity of the 
mitochondrial membrane (Benard et al., 2007; Benard and Rossignol, 2008). Although Drp1 has 
been implicated in mitochondrial positioning at the immune synapse (Baixauli et al., 2011), 
lymphocyte chemotaxis (Campello et al., 2006), and ROS production (Roth et al., 2014) during 
T cell activation, our data suggest that in addition to these processes, fission underlies the 
reprogramming of cells to aerobic glycolysis. 
 
We show that IL-2 TE cells have a mitochondrial structure that is more susceptible to digitonin 
disruption when compared to IL-15 TM cells, which suggests a more exposed membrane with 
less densely packed protein complexes. This relatively enhanced permeability however, does not 
mean that their mitochondria are damaged, or unable to function. In fact, although TE cells have 
less efficient OXPHOS in terms of how it is coupled to ATP synthesis, TE cells are very 
metabolically active with high OCR and ECAR (Chang et al., 2013; Sena et al., 2013). Our 
experiments involving pharmacological enforcement of mitochondrial fusion promoted OCR and 
SRC (and ECAR, albeit to a lesser extent) in IL-2 TE cells. The drug modified cells maintained 
full TE cell function with no effect on their cytolytic ability or proliferation, but possessed 
enhanced cytokine expression. Fusion and/or cristae tightening boosted the TE cells’ oxidative 
capacity, endowing them with longevity and persistence, while their higher aerobic glycolysis 
supported increased cytokine production, which may explain their superior antitumor function. 
 
Our data suggest a model where morphological changes in mitochondria are a primary signal that 
shapes metabolic reprogramming during cellular quiescence or activation. We speculate that 
fission associated expansion of cristae as a result of TCR stimulation physically separates ETC 
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complexes, decreasing ETC efficiency. With delayed movement of electrons from complex I 
down the ETC, NADH levels rise in the mitochondria, slowing forward momentum of the TCA 
cycle and cause an initial drop in ATP. To correct redox balance, cells will export pyruvate to 
lactate to regenerate NAD+ in the cytosol, which can enter the mitochondria through various 
shuttles to restore redox balance (Dawson, 1979) and increase flux through glycolysis to restore 
ATP levels, all contributing to the Warburg effect in activated T cells. When cristae are tightly 
configured, the ETC works efficiently and maintains entrance of pyruvate into the mitochondria 
with a favorable redox balance. In this case, cristae morphology as a result of fusion directs TM 
cell formation and retains these cells in a quiescent state. Thus, mitochondrial dynamics control 
the balance between metabolic pathway engagement and T cell fate.  
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Figure 18. Mitochondrial dynamics controls T cell fate through metabolic programming. 
 
• TM cells have fused mitochondria while TE cells have fissed mitochondria 
• Mitochondrial fusion protein Opa1 is required for TM cells and not TE cells 
• Enforcing fusion improves adoptive cellular immunotherapy against tumors 
• Cristae remodeling via fusion/fission signals metabolic adaptations in T cells 
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